

1 **TITLE:**

2 **Microbial signatures in the lower airways of mechanically ventilated COVID19**
3 **patients associated with poor clinical outcome**

4
5 *Imran Sulaiman^{1,2}, Matthew Chung³, Luis Angel^{1,2}, Jun-Chieh J. Tsay^{1,2,4}, Benjamin G.*
6 *Wu^{1,2,4}, Stephen T. Yeung⁵, Kelsey Krolkowski^{1,2}, Yonghua Li^{1,2}, Ralf Duerr⁵,*
7 *Rosemary Schluger^{1,2}, Sara A. Thannickal⁵, Akiko Koide^{2,6}, Samaan Rafeq^{1,2}, Clea*
8 *Barnett^{1,2}, Radu Postelnicu^{1,2}, Chang Wang⁷, Stephanie Banakis³, Lizzette Perez-*
9 *Perez⁸, George Jour⁹, Guomiao Shen⁹, Peter Meyn¹⁰, Joseph Carpenito^{1,2}, Xiuxiu*
10 *Liu^{1,10}, Kun Ji^{1,11}, Destiny Collazo^{1,2}, Anthony Labarbiera^{1,2}, Nancy Amoroso^{1,2}, Shari*
11 *Brosnahan^{1,2}, Vikramjit Mukherjee^{1,2}, David Kaufman^{1,2}, Jan Bakker^{1,2}, Anthony*
12 *Lubinsky^{1,2}, Deepak Pradhan^{1,2}, Daniel H. Sterman^{1,2}, Michael Weiden^{1,2}, Adriana*
13 *Hegu^{9,12}, Laura Evans¹³, Timothy M. Uyeki¹⁴, Jose C. Clemente¹⁵, Emmie De wit⁸, Ann*
14 *Marie Schmidt¹⁶, Bo Shopsin¹⁷, Ludovic Desvignes⁵, Chan Wang¹⁸, Huilin Li¹⁸, Bin*
15 *Zhang¹⁹, Christian V. Forst¹⁹, Shohei Koide^{6,20}, Kenneth A. Stapleford⁵, Kamal M.*
16 *Khanna^{5,6}, Elodie Ghedin^{3,7*}, and Leopoldo N. Segal^{1,2,6*}*

17
18 ¹Division of Pulmonary and Critical Care Medicine, New York University Grossman
19 School of Medicine, NYU Langone Health, New York, NY

20 ² Department of Medicine, New York University Grossman School of Medicine, NYU
21 Langone Health, New York, NY

22 ³Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of
23 Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

24 ⁴Division of Pulmonary and Critical Care Medicine, VA New York Harbor Healthcare
25 System, NY

26 ⁵ Department of Microbiology, New York University Grossman School of Medicine, NYU
27 Langone Health, New York, NY.

28 ⁶ Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine,
29 NYU Langone Health, New York, NY.

30 ⁷ Center for Genomics & Systems Biology, Department of Biology, New York University
31 New York, NY

32 ⁸ Molecular Pathology Unit, Laboratory of Virology, National Institute of Allergy and
33 Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories,
34 Hamilton, MT

35 ⁹ Department of Pathology, New York University Grossman School of Medicine, NYU
36 Langone Health, New York, NY.

37 ¹⁰ Division of Pediatrics, Longhua Hospital Affiliated to Shanghai University of Chinese
38 Medicine, CN

39 ¹¹ Dongfang Hospital affiliated to Beijing University of Traditional Chinese Medicine,
40 Beijing, China

41 ¹² NYU Langone Genome Technology Center, New York University Grossman School
42 of Medicine, NYU Langone Health, New York, NY

43 ¹³ Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, USA

44 ¹⁴ Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA

45 ¹⁵ Department of Genetics and Genomic Sciences and Immunology Institute, Icahn
46 School of Medicine at Mount Sinai, NY.

47 ¹⁶ Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism,
48 Department of Medicine, New York University Grossman School of Medicine, NYU
49 Langone Health, New York, NY

50 ¹⁷ Division of Infectious Diseases, Department of Medicine, New York University School
51 of Medicine, NYU Langone Health, New York, NY

52 ¹⁸ Department of Population Health, New York University School of Medicine, NYU
53 Langone Health, New York, NY

54 ¹⁹ Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and
55 Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY

56 ²⁰ Department of Biochemistry and Molecular Pharmacology, New York University
57 Grossman School of Medicine, NYU Langone Health, New York, NY
58 and Perlmutter Cancer Center, New York, NY 10016

59

60

61 Imran Sulaiman, MD, PhD SheikMohammadImran.Sulaiman@nyumc.org

62 Matthew Chung, PhD matt.chung@nih.gov

63 Luis Angel, MD Luis.Angel@nyulangone.org

64 Jun-Chieh J. Tsay, MD jun-chieh.tsay@nyumc.org

65 Benjamin G. Wu, MD Benjamin.Wu@nyumc.org

66 Stephen Yeung, PhD Stephen.Yeung@nyulangone.org

67 Kelsey Krolikowski Kelsey.Krolikowski@nyulangone.org

68 Yonghua Li, MD, PhD Yonghua.Li@nyumc.org

69 Ralf Duerr, MD, PhD Ralf.Duerr@nyulangone.org

70 Rosemary Schluger, RN rosemary.schluger@nyumc.org

71 Sara A. Thannickal, BS Sara.thannickal@nyulangone.org

72 Akiko Koide, PhD, Akiko.Koide@nyulangone.org

73 Samaan Rafeq, MD Samaan.Rafeq@nyulangone.org

74 Clea Barnett, MD Clea.Barnett@nyulangone.org

75 Radu Postelnicu, MD Radu.Postelnicu@nyulangone.org

76 Chang Wang, PhD cw2505@nyu.edu

77 Stephanie Banakis stephanie.banakis@nih.gov

78 Lizzette Perez-Perez lizzette.perez-perez@nih.gov

79 George Jour, PhD George.Jour@nyulangone.org

80 Guomiao Shen, PhD Guomiao.Shen@nyulangone.org

81 Peter Meyn peter.meyn@nyumc.org

82 Joseph Carpenito Joseph.carpenito@nyumc.org

83 Xiuxiu Liu, MS liuxiuxiu_longhua@outlook.com

84 Kun Ji, MD, PhD Kun.Ji@nyulangone.org

85 Destiny Collazo Destiny.Collazo@nyulangone.org

86 Anthony Labarbiera Anthony.Labarbiera@nyulangone.org

87 Nancy Amoroso, MD Nancy.Amoroso@nyulangone.org

88 Shari Brosnahan, MD Shari.Brosnahan@nyulangone.org

89 Vikramjit Mukherjee, MD Vikramjit.Mukherjee@nyulangone.org

90 David Kaufman, MD David.A.Kaufman@nyulangone.org

91 Jan Bakker, MD, PhD Jan.Bakker@nyulangone.org

92 Anthony Lubinsky, MD Anthony.Lubinsky@nyulangone.org

93 Deepak Pradhan, MD Deepak.Pradhan@nyulangone.org

94 Daniel H. Serman, MD Daniel.sterman@nyumc.org

| | | |
|-----|----------------------------|-----------------------------------|
| 95 | Michael Weiden, MD | Michael.Weiden@nyulangone.org |
| 96 | Adriana Heguy, PhD | Adriana.heguy@nyumc.org |
| 97 | Laura Evans, MD | leevans@uw.edu |
| 98 | Timothy M. Uyeki, MD, MPH | tmu0@cdc.gov |
| 99 | Jose C. Clemente, PhD | jose.clemente@mssm.edu |
| 100 | Emmie De wit | emmie.dewit@nih.gov |
| 101 | Ann Marie Schmidt, MD | AnnMarie.Schmidt@nyulangone.org |
| 102 | Bo Shopsin, MD, PhD | Bo.Shopsin@nyulangone.org |
| 103 | Ludovic Desvignes, PhD | Ludovic.Desvignes@nyulangone.org |
| 104 | Chan Wang, PhD | Chan.Wang@nyulangone.org |
| 105 | Huilin Li, PhD | Huilin.Li@nyulangone.org |
| 106 | Bin Zhang, PhD | bin.zhang@mssm.edu |
| 107 | Christian V. Forst, PhD | christian.forst@mssm.edu |
| 108 | Shohei Koide, PhD | Shohei.Koide@nyulangone.org |
| 109 | Kenneth A. Stapleford, PhD | Kenneth.Stapleford@nyulangone.org |
| 110 | Kamal Khanna, PhD | Kamal.Khanna@nyulangone.org |
| 111 | Elodie Ghedin, PhD | elodie.ghedin@nih.gov |
| 112 | Leopoldo N. Segal, MD | Leopoldo.Segal@nyumc.org |

113
114 *Corresponding Authors: Elodie Ghedin (elodie.ghedin@nih.gov) and Leopoldo N.
115 Segal, (Leopoldo.Segal@nyumc.org)

116
117

118 **Authors Contributions:**

119 Study conception and design: IS, LA, LD, SK, KS, KK, EG, LNS
120 Data was obtained by: IS, LA, SY, KK, YL, RD, RS, SAT, AK, SR, CB, RP, GJ, GS, PM,
121 JC, XL, KJ, DC, AL, NA, SB, VM, DK, JB, AL, DP, LPP, EDW, DHS, AH, LNS
122 Data were analyzed by: IS, MC, JCJT, BGW, SY, KK, RD, CW, JCC, CW, HL, CVF, BZ,
123 SK, KS, EG, LNS
124 The first draft of the manuscript was written by: IS, MC, LA, EG, LNS
125 All authors read, critically revised and approved the final manuscript.

126

127 **Research support funding:**

128 R37 CA244775 (LNS, NCI/NIH); R01 HL125816 (LNS, SBK, NHLBI/NIH); Colton Pilot
129 Project Grant (LNS, LA, SBL, KK); UWSC12030 (LNS, RP, LE, CDC Foundation);
130 PACT grant (LNS, FNIH); R21 AI158997 (SK); R01 AI143861 (KMK, NIAID/NIH); R01
131 AI143861-02S1 (KMK, NIAID/NIH); R01 DK110014 (HL and CW, NIDDK/NIH); P20
132 CA252728 (CW and HL, NCI/NIH) American Association for Cancer Research Grant
133 (HP/LNS); The Genome Technology Center is partially supported by the Cancer Center
134 Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center (AH,
135 AT); FAMRI Young Clinical Scientist Award (BGW), Stony Wold-Herbert Fund Grant-in-
136 Aid/Fellowship (IS, CB). This work was supported in part by the Division of Intramural
137 Research (DIR) of the NIAID/NIH (EG, EDW).

138

139 **Acknowledgement:**

140 We would like to thank the Genome Technology Center (GTC) for expert library
141 preparation and sequencing, and the Applied Bioinformatics Laboratories (ABL) for
142 providing bioinformatics support and helping with the analysis and interpretation of the

143 data. Experimental Pathology Research Laboratory for histopathology services and
144 imaging. GTC and ABL are shared resources partially supported by the Cancer Center
145 Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. This
146 work has used computing resources at the NYU School of Medicine High Performance
147 Computing Facility (HPCF). Financial support for the PACT project is possible through
148 funding support provided to the FNIH by: AbbVie Inc., Amgen Inc., Boehringer-
149 Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb, Celgene Corporation,
150 Genentech Inc., Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of
151 Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and
152 Sanofi. The findings and conclusions in this report are those of the authors and do not
153 necessarily represent the official position of the Centers for Disease Control and
154 Prevention.

155

156

157

158 Running Head: COVID-19

159

160

161 Word Count: 4869

162 Body of the manuscript:

163

164

165 Financial Disclosure: None

166

167

168 Key words: microbiome, virome, severe acute respiratory syndrome

169

170

171

172

173

174

175 **Abstract:**

176 Mortality among patients with COVID-19 and respiratory failure is high and there are no known
177 lower airway biomarkers that predict clinical outcome. We investigated whether bacterial
178 respiratory infections and viral load were associated with poor clinical outcome and host
179 immune tone. We obtained bacterial and fungal culture data from 589 critically ill subjects with
180 COVID-19 requiring mechanical ventilation. On a subset of the subjects that underwent
181 bronchoscopy, we also quantified SARS-CoV-2 viral load, analyzed the microbiome of the lower
182 airways by metagenome and metatranscriptome analyses and profiled the host immune
183 response. We found that isolation of a hospital-acquired respiratory pathogen was not
184 associated with fatal outcome. However, poor clinical outcome was associated with enrichment
185 of the lower airway microbiota with an oral commensal (*Mycoplasma salivarium*), while high
186 SARS-CoV-2 viral burden, poor anti-SARS-CoV-2 antibody response, together with a unique
187 host transcriptome profile of the lower airways were most predictive of mortality. Collectively,
188 these data support the hypothesis that 1) the extent of viral infectivity drives mortality in severe
189 COVID-19, and therefore 2) clinical management strategies targeting viral replication and host
190 responses to SARS-CoV-2 should be prioritized.

191

192

193

194

195

196

197

198 **Introduction**

199 The earliest known case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
200 CoV-2) infection causing coronavirus virus disease (COVID-19) is thought to have
201 occurred on November 17, 2019¹. As of February 20, 2021, 110.3 million confirmed
202 cases of COVID-19 and 2.4 million deaths have been reported worldwide². As the
203 global scientific community rallied in a concerted effort to understand SARS-CoV-2
204 infections, our background knowledge is rooted in previous experience with the related
205 zoonotic betacoronaviruses Middle East Respiratory Syndrome coronavirus (MERS-
206 CoV) and SARS-CoV-1 that have caused severe pneumonia with 34.4% and 9% case
207 fatality, respectively³. As observed for these related coronaviruses, SARS-CoV-2
208 infection can result in an uncontrolled inflammatory response⁴ leading to acute
209 respiratory distress syndrome (ARDS) and multi-organ failure, both associated with
210 increased mortality. While a large proportion of the SARS-CoV-2 infected population is
211 asymptomatic or experiences mild illness, a substantial number of individuals will
212 develop severe disease and require hospitalization, with some progressing to
213 respiratory failure. Mortality among hospitalized COVID-19 patients is estimated to be
214 approximately 20%, which can go up to 70% among those requiring invasive
215 mechanical ventilation⁵⁻¹².

216
217 Mortality in other viral pandemics, such as the 1918 H1N1 and 2009 H1N1 influenza
218 pandemics, has been attributed in part to bacterial co-infection or super-infection^{13,14}.

219 To determine if this is also the case for COVID-19, we can use next generation
220 sequencing (NGS) to probe the complexity of the microbial environment (including RNA
221 and DNA viruses, bacteria and fungi) and how the host (human) responds to infection.

222 Recent studies have used this approach to uncover microbial signatures in patients with
223 ARDS.^{15,16} Increased bacterial burden and the presence of gut-associated bacteria in
224 the lung were shown to worsen outcomes in these critically ill patients^{15,17}, highlighting
225 the potential role of the lung microbiome in predicting outcomes in ARDS. In a recent
226 study using whole genome sequencing to profile the gut microbiome of 69 patients from
227 Hong Kong, investigators identified an increased abundance of opportunistic fungal
228 pathogens among patients with confirmed COVID-19¹⁸. While there is emerging interest
229 in understanding the microbial environment in patients with SARS-CoV-2 infections, few
230 studies have attempted to characterize this at the primary site of the disease activity:
231 the lower airways^{19,20}. Furthermore, no study has yet determined whether microbial
232 differences in the airways of COVID-19 patients could be contributing to the different
233 outcomes in patients receiving mechanical ventilation.

234
235 In this investigation, we accessed a large prospective cohort of critically ill patients with
236 SARS-CoV-2 infection who required invasive mechanical ventilation, and from whom
237 bronchoalveolar lavage (BAL) samples were collected. We characterized the lung
238 microbiome of these patients in parallel with analyses of lower airway markers of host
239 immunity. While we did not find that isolation of a secondary respiratory pathogen was
240 associated with prolonged mechanical ventilation (>28 days) or fatal outcome, we did
241 identify critical microbial signatures—characterized by enrichment of oral commensals,
242 high SARS-CoV-2 load, and decreased anti-SARS-CoV-2 IgG response—associated
243 with fatal outcome, suggesting a need for more targeted antiviral therapeutic
244 approaches for the care of critically ill COVID19 patients.

245

246 **Results**

247 Cohort

248 From March 3rd to June 18th 2020, a total of 589 patients with laboratory-confirmed
249 SARS-CoV-2 infection were admitted to the intensive care units of two academic
250 medical centers of NYU Langone Health in New York (Long Island and Manhattan) and
251 required invasive mechanical ventilation (MV). This included a subset of 142 patients
252 from the Manhattan campus who underwent bronchoscopy for airway clearance and/or
253 tracheostomy from which we collected and processed lower airway samples for this
254 investigation (**Supplementary Fig. 1**). **Table 1** shows demographics and clinical
255 characteristics of the 142 patients who underwent bronchoscopy divided into three
256 clinical outcomes: survivors with ≤ 28 Days on MV; survivors with >28 Days on MV; and
257 deceased. The median post admission follow-up time was 232 days (CI=226-237 days).
258 **Supplementary Tables 1** and **2** compare similar data across all 589 subjects, divided
259 per site and sub-cohorts. Patients at the Manhattan campus who underwent
260 bronchoscopy were younger, had lower body mass index (BMI), and a lower prevalence
261 of chronic obstructive pulmonary disease (COPD; **Supplementary Table 1**). Among the
262 cohort that provided lower airway samples through bronchoscopy, 37% of the subjects
263 were successfully weaned within 28 days of initiation of MV and survived
264 hospitalization, 39% required prolonged MV but survived hospitalization, and 23% died.
265 Patients within the bronchoscopy cohort had a higher overall survival than the rest of
266 the NYU COVID-19 cohort since most critically ill patients were not eligible for
267 bronchoscopy or tracheostomy. Mortality among those in the no-bronchoscopy cohort
268 was 77%. In the overall NYU cohort, higher age and BMI were associated with
269 increased mortality (**Supplementary Table 2**). There was a similar, albeit non-

270 significant, trend for the bronchoscopy cohort. Among the clinical characteristics of this
271 cohort, patients within the deceased group more commonly had a past medical history
272 of chronic kidney disease and cerebrovascular accident.

273 Study patients were admitted during the first wave of the pandemic in the US, prior to
274 current standardized management of COVID-19. Within the bronchoscopy cohort, more
275 than 90% of the subjects received hydroxychloroquine and anticoagulation (therapeutic
276 dose), 69% received corticosteroids, 41% received tocilizumab (anti-Interleukin (IL)-6
277 receptor monoclonal antibody), 21% required dialysis, and 18.9% were started on
278 extracorporeal membrane oxygenation (ECMO) (**Table 1**). Antimicrobial therapy
279 included use of antivirals (lopinavir/ritonavir in 16% and remdesivir in 10%), antifungals
280 (fluconazole in 40% and micafungin in 57%), and antibiotics (any, in 90% of the
281 subjects). Among the factors associated with clinical outcome within the bronchoscopy
282 cohort, patients who survived were more commonly placed on ECMO whereas patients
283 who died had frequently required dialysis (**Table 1**); these trends were also observed
284 across the whole NYU cohort. Neither hydroxychloroquine or azithromycin were
285 significantly associated with clinical outcome; however, patients who survived were
286 more frequently treated with the combination antibiotic piperacillin/tazobactam.

287
288 Within the first 48hrs from admission, respiratory bacterial cultures were rarely obtained
289 (n=70/589, 12%) with very few positive results (n=12, 17%). Blood cultures were more
290 commonly obtained (n=353/589, 60%) but the rate of bacterial culture positivity was
291 much lower (n=5, 1.4%). These data support that community acquired bacterial co-
292 infection was not a common presentation among critically ill COVID-19 patients.

293

294 During their hospitalization, most patients had respiratory and/or blood specimens
295 collected for bacterial cultures (**Table 1** and **Supplementary Table 1**). The proportions
296 of positive bacterial respiratory cultures and blood cultures were 73% and 43%,
297 respectively. We evaluated whether respiratory or blood culture results obtained as per
298 clinical standard of care were associated with clinical outcome. Risk analyses for the
299 culture results during hospitalization for the whole cohort (n=589) demonstrated that
300 bacterial culture positivity was not associated with increased odds of dying but was
301 associated with prolonged mechanical ventilation in the surviving patients (**Figure 1**).
302 Since length of stay could potentially affect these results (patients who died could have
303 a shorter hospitalization, and therefore may have had fewer specimens collected for
304 cultures), we repeated the analysis using culture data obtained during the first two
305 weeks of hospitalization. This analysis showed that bacterial pathogen culture positivity
306 (both respiratory and blood) during the early period of hospitalization was not
307 associated with worse outcome (**Figure 1** and **Supplementary Table 3**). Interestingly,
308 identification of oral bacteria in respiratory culture, commonly regarded as procedural
309 contaminants, was associated with higher odds of prolonged mechanical ventilation
310 (>28 days) among survivors. Similar trends were noted when analysis was performed
311 on subjects from NYU LI and NYU Manhattan separately, or for the bronchoscopy
312 cohort (**Supplementary Table 2**). Among the bronchoscopy cohort, there was no
313 statistically significant association between culture results and clinical outcome, but
314 there was a trend towards an increased rate of positive respiratory cultures for
315 *Staphylococcus aureus* (including MRSA), *S. epidermidis*, and *Klebsiella pneumoniae* in
316 the survival groups (**Table 1**). These data suggest that in critically ill patients with
317 COVID-19 requiring MV, hospital isolation of a secondary respiratory bacterial pathogen

318 is not associated with worse clinical outcome.

319

320 *SARS-CoV-2 load in the lower airways is associated with poor clinical outcome*

321 Using supraglottic and BAL samples from patients undergoing bronchoscopy (n=142),
322 we evaluated the viral load by rRT-PCR for the SARS-CoV-2 N gene, adjusted by levels
323 of human ribosomal protein (RP). Of note, the majority of samples were largely obtained
324 in the second week of hospitalization (**Table 1**, median[IQR] = 10[6-14], 13[8-16], and
325 13[8-16] for the ≤ 28 -days MV, >28 -days MV, and deceased groups, respectively, $p=ns$).
326 Paired analysis of upper and lower airway samples revealed that, while there was a
327 positive association between SARS-CoV-2 viral load of the paired samples ($\rho = 0.60$,
328 $p < 0.0001$), there was a subset of subjects (21%) for which the viral load was greater in
329 the BAL than in the supraglottic area, indicating topographical differences in SARS-
330 CoV-2 replication (**Figure 2a**). Importantly, while the SARS-CoV-2 viral load in the
331 upper airway samples was not associated with clinical outcome (**Supplementary Fig.**
332 **2**), patients who died had higher viral load in their lower airways than patients who
333 survived (**Figure 2b**). We then evaluated virus viability in BAL samples by measuring
334 levels of subgenomic RNA (sgRNA) targeting the E gene of SARS-CoV-2. This mRNA
335 is only transcribed inside infected mammalian cells and is not packed into virions, thus,
336 its presence is indicative of viable infecting viral particles in a sample²¹. In BAL, levels of
337 sgRNA correlated with viral load as estimated by rRT-PCR for the SARS-CoV-2 N gene
338 (**Figure 2c**) and the highest percentage of measurable sgRNA was in the deceased
339 group followed by the ≤ 28 -days MV group, and the >28 -days MV group (17.7%, 11.5%,
340 and 3.7%, respectively, chi-square $p=0.028$ for the comparison deceased vs. >28 -days
341 MV group). Thus, while in most cases levels of sgRNA were not measurable in BAL

342 suggesting that there were no viable viral particles in the lower airways of COVID-19
343 patients at the time of bronchoscopy (overall median[IQR] = 12[7-16] days from
344 hospitalization), the lower airway viral burden, as estimated by rRT-PCR, is associated
345 with mortality in critically ill COVID-19 patients.

346

347 *Microbial community structure of the lower airways is distinct from the upper airways in*
348 *critically ill patients.*

349 Considering the bacterial species and the viral loads identified in the lower and upper
350 airways of this cohort and their association with outcomes, we profiled in detail their viral
351 and microbial composition. Microbial communities were evaluated using parallel
352 datasets of RNA and DNA sequencing from 118 COVID-19 patients with lower airway
353 samples that passed appropriate quality control and a subset of paired 64 upper airway
354 samples, along with background bronchoscope controls.

355

356 RNA sequencing (RNAseq) of the metatranscriptome provided insight into the RNA
357 virome as well as the transcriptomes of DNA viruses, bacteria, and fungi. Given the low
358 biomass of lower airway samples we first identified taxa as probable contaminants by
359 comparing the relative abundance between background bronchoscope and BAL
360 samples (**Supplementary Fig. 3a** and **Supplementary Table 4**). However, we did not
361 remove any taxa identified as probable contaminants from subsequent analyses. A
362 comparison of the microbial community complexity captured in these data, determined
363 using the Shannon diversity Index, showed there was significantly lower α diversity in
364 the lower airway samples than in the upper airways and background controls
365 (**Supplementary Fig. 4a**). Similarly, β diversity analysis based on the Bray Curtis

366 Dissimilarity index indicated that the microbial composition of the lower airways was
367 distinct from the upper airways and background controls (**Supplementary Fig. 4b**,
368 PERMANOVA $p < 0.01$). Sequence reads indicated a much higher relative abundance of
369 SARS-CoV-2 in the lower than in the upper airways for this cohort (**Supplementary Fig.**
370 **4c**). Comparisons of the most dominant bacterial and fungal taxa that were functionally
371 active showed that *S. epidermidis*, *Mycoplasma salivarium*, *S. aureus*, *Prevotella oris*,
372 and *Candida albicans*, many often-considered oral commensals, were present in both
373 upper and lower airway samples (**Supplementary Fig. 4c**). Interestingly, the lytic phage
374 Proteus virus Isfahan, known to be active against biofilms of *Proteus mirabilis*²², was
375 found to be highly transcriptionally active in the BAL.

376
377 DNA sequencing data provided insight into the DNA virome, as well as the bacterial and
378 fungal metagenomes. As for the metatranscriptome data, we first identified taxa as
379 probable contaminants but these were not removed for subsequent analyses
380 (**Supplementary Fig. 3b**). Both α and β diversity analyses of the metagenome support
381 distinct microbial community features in the lower airways as compared with the upper
382 airways and background controls (**Supplementary Fig. 5a, 5b**). Among the top 10 taxa
383 across lower and upper airway samples were *S. aureus*, *Salmonella enterica*,
384 *Burkholderia dolosa*, and *Klebsiella variicola*. *Candida albicans* only ranked #77 in the
385 BAL while it was ranked 5th in the metatranscriptome data indicating that while present
386 at low relative abundance, it was highly active (**Supplementary Table 4**). *K. variicola*,
387 while prevalent at a high relative abundance (#4 in BAL, and #5 in the upper airways) in
388 patients of this cohort, its ranking in the RNAseq data was not among the top 50,
389 indicating that it was not as active functionally as other bacteria. Conversely, while *S.*

390 *epidermis* ranked as the most highly functional taxon in both lower and upper airways,
391 based on RNAseq reads (**Supplemental Fig. 3c**), it was 33rd in relative abundance in
392 the BAL DNaseq data but was present at very high relative abundance in the upper
393 airways (ranked #3). These data suggest that microbes that colonize the upper airways
394 and the skin were common in the lower airways in this cohort of COVID-19 patients
395 requiring invasive mechanical ventilation.

396

397 *Distinct microbial signatures are associated with different clinical outcomes.*

398 To determine the potential impact of vertebrate viruses on outcome, we compared virus
399 enrichment differences in BAL samples across the three clinical outcome groups (≤ 28 -
400 days MV, > 28 -days MV, and deceased). As it pertains to the vertebrate RNA virome
401 subfraction, there were significant differences (β diversity) between the three clinical
402 outcome groups (**Supplementary Fig. 6**, PERMANOVA $p < 0.01$). There were no
403 significant differences for the vertebrate DNA virome or DNA virus transcriptome
404 subfractions of the sequence reads (data not shown). Consistent with the SARS-CoV-2
405 viral load assessed by RT-PCR, differential expression analysis (DESeq) of the RNA
406 virome identified SARS-CoV-2 as being enriched in the deceased group, as compared
407 with both ≤ 28 -days and > 28 -days MV groups (fold change > 5 , **Figure 2d**). Cox
408 proportional hazards modeling supports that enrichment with SARS-CoV-2 was
409 associated with increased risk for death (HR 1.33, 95% CI= 1.07-1.67, p value=0.011,
410 FDR adjusted p value=0.06; **Supplementary Table 5**).

411

412 Analysis of differential DNA virus abundance using DEseq did not show statistically
413 significant differences. Because the virome includes viruses of bacteria and archaea,

414 we also analyzed the phage data (including viruses of archaea). Phages impact the
415 bacterial population—including bacterial pathogens—and so could be clinically relevant.
416 At a compositional level, the virome of DNA phages did not display statistically
417 significant differences or significant virus enrichment based on clinical outcome groups
418 (data not shown). However, while the phage metatranscriptome α and β diversity was
419 similar across the clinical outcome groups, there were various taxonomic differences at
420 the RNA level with enrichment of *Staphylococcus* phages CNP \times in the deceased and
421 >28-day MV groups when compared with the \leq 28-day MV group (**Figure 2e**).
422 Differential expression from two other *Staphylococcus* phages was also observed in the
423 >28-days MV group as compared with the \leq 28-days MV group (**Figure 2e**). None of the
424 described taxa were identified as possible contaminants (**Supplementary Table 4**).

425
426 *Enrichment of the lower airway microbiota with oral commensals is associated with poor*
427 *outcome*

428 We evaluated the overall bacterial load by quantitative PCR, targeting the 16S rRNA
429 gene. As expected, the bacterial load in the lower airways was several folds lower than
430 in the upper airways but clearly higher than the background bronchoscope control
431 (**Supplementary Fig. 7**). Patients who died had higher total bacterial load in their lower
432 airways than patients who survived (**Figure 3a**).

433
434 While no statistically significant differences were noted in α or β diversity across clinical
435 outcome groups (**Figure 3b-c**), several differences were noted when differential
436 enrichment was evaluated using DESeq. For the comparisons made across the clinical
437 outcome groups we focused on consistent signatures identified in the lower airway

438 metagenome and metatranscriptome. Coherence of differentially enriched taxa was
439 determined by gene set enrichment analysis (GSEA) (**Figure 3d**) and directionality of
440 enrichment between the two datasets was evaluated (**Figure 3e**). Among the most
441 abundant taxa, the oral commensal *M. salivarum* was enriched in the deceased and
442 >28-days MV groups as compared with the \leq 28-days MV group. In contrast, a different
443 oral commensal, *Prevotella oris*, was enriched in the \leq 28-days MV group as compared
444 with the deceased and >28-days MV groups. These data support that oral commensals
445 are frequently found in the lower airways of critically ill COVID-19 patients and that
446 differences between groups could be due to differential microbial pressures related to
447 host factors. Interestingly, most of the statistically significant taxa were identified in the
448 metatranscriptome rather than in the metagenome data, with only *P. oris* identified in
449 both datasets. None of the described taxa were identified as possible contaminants
450 (**Supplementary Table 4**). Overall, most of the microbial signatures identified as
451 enriched in the deceased or in subjects on prolonged MV are regular colonizers of
452 healthy skin and mucosal surfaces rather than frequent respiratory pathogens.

453
454 For the fungal data, there were no statistically significant differences in α or β diversity
455 identified between clinical outcome groups in the metagenome or the
456 metatranscriptome data (**Supplementary Fig. 8a** and **8c**). However, in the
457 metagenome data, we identified *Candida glabrata* enriched in the deceased group as
458 compared with the \leq 28-days MV and the >28-days MV groups but this was not
459 consistent in the metatranscriptome data (**Supplementary Fig. 8b** and **8d**).

460

461 *Poor clinical outcomes are associated with enrichment of antimicrobial resistance genes*
462 *and glycosphingolipid biosynthesis*

463 We used the gene annotation of the DNaseq and RNAseq data to profile the microbial
464 functional potential of the lower airway samples. For the comparisons made across the
465 clinical outcome groups, we focused on consistent functional signatures identified in the
466 lower airway metagenome and metatranscriptome. Coherence of differentially enriched
467 functions was determined using GSEA (**Figure 4a**) and directionality of enrichment was
468 also evaluated (**Figure 4b**). Overall, there was coherence of directionality between the
469 metatranscriptomics and metagenomics datasets for the comparisons between deceased
470 vs ≤ 28 -days MV, and > 28 -days MV vs ≤ 28 -days MV groups. Interestingly, statistically
471 significant differences were only noted in the metatranscriptome data and not in the
472 metagenome data. Among the top differentially expressed pathways in the poor
473 outcome groups were glycosylases, oxidoreductase activity, transporters, and two-
474 component system, among other genes. The two-component system is used by
475 bacteria and fungi for signaling. A specific analysis of antibiotic resistance genes shows
476 that there was significant gene enrichment and expression of biocide resistance in the
477 deceased group as compared to the two other MV groups (**Supplementary Fig. 9**).
478 There was also significant expression of genes resistant to trimethoprim and phenolic
479 compound, as well as multi drug resistance in the deceased group as compared to the
480 ≤ 28 -days MV group. Presence of the resistance gene against Trimethoprim was not
481 significantly associated with prior exposure with Trimethoprim. However, only 7 patients
482 received this drug before sample collection.

483

484 Lower airway host immune phenotype shows failure of adaptive and innate immune
485 response to SARS-CoV-2 among deceased subjects

486 To evaluate the host immune response to SARS-CoV-2 infection, we first measured
487 levels of anti-Spike and anti-RBD (receptor binding domain) antibodies in BAL samples.
488 For both anti-Spike and anti-RBD immunoglobulins, levels of IgG, IgA and IgM were
489 several logs higher than levels found in BAL samples from non-SARS-CoV-2 infected
490 patients. Importantly, IgG levels of anti-Spike and anti-RBD were significantly lower in
491 the deceased group as compared to the levels found in patients who survived (**Figure**
492 **5a** and **Supplementary Fig. 10a-c**, $p < 0.05$). A neutralization assay performed using
493 BAL fluid showed varying levels of neutralization across all samples (as estimated by
494 EC50) but no statistically significant differences between the clinical outcome groups
495 (**Supplementary Fig. 10d**). We then evaluated whether levels of antibodies correlated
496 with viral load in BAL samples. While viral load levels of SARS-CoV-2 measured with
497 rRT-PCR did not correlate with BAL measurements of SARS-CoV-2 specific antibodies,
498 sgRNA viral load levels negatively correlated with BAL levels of Anti-Spike (IgG and
499 IgA), Anti-RBD (IgG and IgA) and the Neutralization assay (**Supplementary Table 6**).
500 These data suggest that the IgG subfraction is an important marker of the adaptive
501 immune response in the lung of critically ill COVID-19 patients and that both sub-
502 fractions of IgG and IgA anti-SARS-CoV-2 may contribute to the viral replication control
503 in the lower airways.

504
505 Host transcriptome analyses of BAL samples showed significant differences across
506 clinical outcome groups based on β diversity composition (**Supplementary Fig. 11**). We
507 identified multiple differentially expressed genes across the clinical outcome groups

508 **(Supplementary Fig. 11b-d)**. First, we noted that the lower airway transcriptomes
509 showed downregulation of heavy constant of IgG (IGHG3), and heavy constant of IgA
510 (IGHA1) genes in those with worse clinical outcome **(Supplementary Table 7)**. We
511 then used IPA (Ingenuity Pathway Analysis) to summarize differentially expressed
512 genes across the three clinical outcome groups **(Figure 5b)**. The sirtuin Signaling
513 Pathway (a pathway known to be involved in aging, gluconeogenesis/lipogenesis, and
514 host defense against viruses)²³ and the ferroptosis pathway (an iron-dependent form of
515 regulated cell death present in bronchial epithelium)^{24,25} were both upregulated in those
516 with worse outcome. While this may reflect the host response to viral infection, other
517 differences in the transcriptomic data showed downregulation of mitochondrial oxidative
518 phosphorylation, HIF1 α , STAT3, and Phospholipase C Signaling. Additional canonical
519 signaling pathways, including insulin secretion, multiple Inositol related pathways,
520 noradrenaline/adrenaline degradation signaling, and xenobiotic related metabolism
521 were significantly downregulated when comparing the >28-days MV vs. \leq 28-days MV
522 groups. Upstream pathway prediction analyses of the host airway transcriptome support
523 previously reported mitochondria dysfunction²⁶ (inhibition in mitochondrial related
524 regulators NSUN3, MRPL14, MRPL12, LONP1, DAP3), and metabolic/gluconeogenesis
525 dysregulation^{27,28} (SIRT3) in critically ill COVID-19 subjects with poor outcome
526 **(Supplementary Table 8)**. We also observed decreased activation in the inflammatory
527 response in critically ill COVID-19 subjects with poor outcome (phagocytes, neutrophils,
528 and granulocytes, and leukocytes; **Supplementary Table 9**). A comparison of clinical
529 outcome between the >28-days MV vs. \leq 28-days MV groups showed upstream
530 predicted inhibition in insulin, estrogen, beta-estradiol, EGF, EGFR, IL-5, and IL-10RA
531 in the >28-days MV group **(Supplementary Table 9)**. These differences suggest that, at

532 the stage that we sampled the lower airways of patients with critically COVID-19, an
533 overt inflammatory tone was not predictive of worst outcome.

534

535 To determine if the abundance of immune cells varies between different clinical
536 outcome groups, we estimated cell type abundance from the host transcriptome with
537 computational cell type quantification methods, including a deconvolution approach
538 implemented in CIBERSORTx²⁹ and a cell type signature enrichment approach
539 implemented in xCell³⁰. As reported recently in other studies³¹, among the cell types
540 detected in the BAL samples we observed a consistent enrichment of mast cells and
541 neutrophils in the >28-days MV and deceased groups compared with the ≤28-days MV
542 group (**Figure 5c** and **Supplementary Table 10**). We also identified significantly higher
543 inflammatory macrophages (M1), innate T-cells and memory T-cells (CCR7⁺) among
544 subjects with worse clinical outcome.

545

546 *Cross-kingdom network analyses identify bacteria, fungi, and host pathways functionally*
547 *impacted by SARS-CoV-2*

548 To identify potential microbe-microbe and microbe-host interactions that could have an
549 effect on outcome, we used a multi-scale network analysis approach (Multiscale
550 Embedded Gene co-Expression Network Analysis, MEGENA)³². We first used the
551 relative abundance from the RNAseq data to capture co-expressing taxa in the
552 metatranscriptome network neighborhood of SARS-CoV-2 (SARS2-NWN). We
553 examined five such network neighborhoods (constructed by including nodes with
554 increasing distance 1 to 5 from SARS-CoV-2, i.e. neighborhood 1 to neighborhood 5)
555 that were significantly enriched for taxa functionally active in the deceased group when

556 compared with the ≤ 28 -day MV group. Only the largest cluster, with 504 taxa, had
557 significantly enriched taxa in both the deceased and in the ≤ 28 -day MV outcome groups
558 (**Supplementary Fig. 12a**) (FET P-value = $4.6e-45$, 4.0 FE). Many of these taxa are
559 among the top 50 most abundant microbes we had previously identified in the
560 metatranscriptome dataset. Taxa present that are influenced by SARS-CoV-2 and
561 significantly differentially enriched in the deceased group include bacteria such as *M.*
562 *salivarium*, *Bifidobacterium breve*, and *Lactobacillus rhamnosus* (a gut commensal),
563 that we had previously identified by differential expression analysis (**Figure 3e**), but also
564 taxa such as *S. epidermis*, *Mycoplasma hominis* (urogenital bacteria), and the phage
565 VB_PmiS-Isfahan (also referred to as Proteus virus Isfahan) that we had previously
566 only picked up as being highly abundant but not necessarily differentially enriched in the
567 deceased group. Most of the fungi, such as *C. albicans*, *C. glabrata* and *C. orthopsilosis*
568 were enriched in the ≤ 28 -day MV group. Interestingly, our earlier analysis of the
569 metagenome (**Supplementary Fig. 8b**) had identified *C. glabrata* as being enriched in
570 the deceased group with no enrichment in the metatranscriptome. This analysis
571 indicates that some of these abundant taxa could be responding to SARS-CoV-2
572 disruption in a similar manner, or indirectly interacting functionally.

573

574 We further investigated the association of the network neighborhood with host network
575 modules using the host transcriptome data to identify groups of host genes that are co-
576 expressed in response to SARS-CoV-2 disruption. The 3 host modules with the most
577 significant correlations to SARS2-NWN are M175, M277 and M718. M277 is the parent
578 module of M718, and both are enriched with genes related to respiratory electron
579 transport, while M175 is enriched for IFN- γ signaling (**Supplementary Fig. 12b**).

580 Module M175 is positively correlated with the SARS2-NWN ($\rho = 0.32$, P-value = $2.1e-3$).
581 While there was no collective enrichment of the module by differentially expressed
582 genes (DEGs) in the deceased vs ≤ 28 -days MV, there was for > 28 -days vs ≤ 28 -days
583 MV (FET P-value = 0.030, 4.5 FE). This module includes well-known antiviral IFN
584 stimulated genes (ISGs), such as *IRF7* and *OASL*. Investigating module response on an
585 individual gene level, Interleukin 4 induced 1 (*IL4I1*) appears as one of the most up-
586 regulated genes in this module when comparing the deceased group with the ≤ 28 -day
587 MV group. The transporter 1, ATP binding cassette subfamily B member (*TAP1*) is also
588 upregulated and a key regulator (hub gene). Together with *TAP2*, *TAP1* plays a central
589 role in MHC I antigen presentation³³. Transcriptional regulators *SP110* and *SP140*, both
590 ISGs and also identified as hub genes, were down-regulated. Module 718 was also
591 positively correlated with the SARS2-NWN ($\rho = 0.31$, P-value = $1.3e-3$; enrichment FET
592 P-value = 0.029, 3.7 FE of M178 by differentially expressed genes in deceased vs ≤ 28 -
593 days MV). The majority of genes in this module are down-regulated in the deceased
594 group compared with the ≤ 28 -day group. Some of the genes encode subunits of the
595 mitochondrial ATP synthase, such as *ATP6* and *ATP8*, the cytochrome C oxidase, with
596 *COX2* and *COX3* as well as the NADH dehydrogenase complex, such as *ND1-ND6*.
597 *ND4L*, *ATP6*, *COX2*, *ND1*, *ND3*, *ND4L* and *ND6* are key regulators, potentially
598 modulating the expression of the other genes in the module. These findings further
599 support mitochondria dysfunction²⁶, potentially disrupting processes indicated by the
600 module. Other down-regulated genes are humanin1 (*MTRNR2L1*) and R-spondin 1
601 (*RSPO1*). Humanin is known to protect against oxidative stress and mitochondrial
602 dysfunction³⁴. *RSPO1* protects against cell stress by activating the Wnt/ β -catenin
603 signaling pathway³⁵. Non-coding RNAs, such as *MALAT1* and *RHOQ-AS1* were found

604 to be up-regulated. *MALAT1* is known to suppress IRF3-initiated antiviral innate
605 immunity³⁶ while the function of *RHOQ-AS1* is unknown.

606

607

608 *Metatranscriptome and Transcriptome signatures are predictive of mortality*

609 We evaluated the strength of the metatranscriptomic, metagenomic and host
610 transcriptomic profiles to predict mortality in this cohort of critically ill COVID-19 patients.

611 To this end, we identified features in each of these datasets and constructed risk scores

612 that best predicted mortality. **Figure 6a** shows that the metatranscriptome data, alone or

613 combined with the other two datasets, was most predictive of mortality. Importantly, the

614 predictive power (as estimated by the area under the curve) of the metatranscriptome

615 data was improved by excluding probable contaminants and worsened when SARS-

616 CoV-2 was removed from the modeling. The selected features we used to construct the

617 metatranscriptome, metagenome and host transcriptome risk scores are reported in

618 **Supplementary Table 11**). Using the means of the scores, we classified all subjects

619 into high risk and low risk groups for mortality. **Figure 6b** shows Kaplan-Meier survival

620 curve comparisons evaluating the predictive power of risk score stratification based on

621 metatranscriptome, metagenome and host transcriptome data. Combining risk scores

622 from different datasets showed an optimal identification of mortality when

623 metatranscriptome and host transcriptome were considered (**Figure 6c**). We then used

624 the gene signature found as being the most predictive of mortality to conduct IPA

625 analyses. Among the upstream regulators, mortality was associated with predicted

626 activation of interferon alpha while chemotaxis and infection by RNA virus were

627 predicted as activated in diseases and functions. These data highlight the importance of

628 SARS-CoV-2 abundance in the lower airways as a predictor for mortality, and the
629 significant contribution of the host cell transcriptome, which reflects the lower airway cell
630 response to infection.

631 **Discussion**

632 A limited number of studies to date have evaluated the lower airway microenvironment
633 in patients with SARS-CoV-2 infection because of the increased risk of virus
634 transmission to healthcare providers during sampling^{19,20,37-42}. This has limited
635 molecular investigations into the primary site of the disease. Having built a substantial
636 biorepository of lower airway samples among COVID-19 patients on mechanical
637 ventilation recruited during the first wave of SARS-CoV-2 infections in New York City,
638 we used a metagenomic approach to characterize the microbiome in the lower airways
639 and assessed its impact on clinically meaningful outcomes. In this analysis of 142
640 critically ill hospitalized patients with confirmed SARS-CoV-2 infection and lower airway
641 biorepository samples available, we determined that higher SARS-CoV-2 viral load,
642 higher relative abundance of *Mycoplasma salivarium*, and limited anti-SARS-CoV-2
643 Spike protein IgG response in the lower airways were associated with increased
644 mortality. This signature was supported by the metatranscriptome data of the lower
645 airway samples where SARS-CoV-2 sequence reads were significantly enriched in
646 those patients who died compared to those who survived after developing respiratory
647 failure requiring mechanical ventilation. Importantly, although we observed changes in
648 other microbial components of the lower airway microbiome in our analysis of lower
649 airway samples from 118 patients and by clinical laboratory culture results obtained
650 from 589 patients, we did not find evidence to support the hypothesis that co-infection
651 with common (bacterial, viral, fungi) respiratory pathogens was associated with poor
652 outcome—although most patients received empiric treatment with broad spectrum
653 antibiotics and anti-fungals.

654

655 Several studies have explored the relationship between SARS-CoV-2 viral load and
656 mortality⁴³⁻⁴⁸. Severe influenza requiring hospitalization has also been associated with
657 higher viral loads^{49,50}. It has been argued that high viral load might merely be a
658 reflection of an individual's immune response⁴³. In fact, in SARS-CoV-1, clinical
659 progression was not associated with increased viral load or uncontrolled viral replication
660 in the nasopharynx but rather with an upregulated immune profile in these patients⁵¹. In
661 a large cohort of 1145 patients with confirmed SARS-CoV-2, viral load measured in
662 nasopharyngeal swab samples was found to be significantly associated with mortality,
663 even after adjusting for age, sex, race and several co-morbidities⁴⁸. Similar results were
664 found in a cohort of patients in New York City with or without cancer, where in-hospital
665 mortality was significantly associated with a high SARS-CoV-2 viral load in the upper
666 airways⁴⁷. The data presented here through the use of direct quantitative methods
667 (RT-PCR) and a semiquantitative untargeted approach (metatranscriptome sequencing)
668 support the hypothesis that the SARS-CoV-2 viral load in the lower airways plays a
669 critical role in the clinical progression of critically ill COVID-19 patients. It is important to
670 note that current guidelines for treatment of COVID-19 do not recommend treatment
671 with remdesivir for patients receiving invasive mechanical ventilation⁵². The results of
672 this investigation suggest that antivirals might still have a role in the treatment of
673 critically ill COVID-19 patients.

674

675 We investigated the possibility that mortality with SARS-CoV-2 infection was related to
676 co-infection with other pathogens. To this point several investigations have shown
677 evidence of SARS-CoV-2 co-infection with other viruses, bacteria and fungi identified by
678 culture-based techniques^{18,53-60}. In a cohort of 116 specimens positive for SARS-CoV-

679 2, 21% were positive for one or more additional respiratory pathogens including
680 rhinovirus/enterovirus and respiratory syncytial virus⁵³. In a meta-analysis of 3,338
681 patients with COVID-19, only 3.5% of patients had an identified bacterial co-infection at
682 admission, while 14.3% were found later to have a secondary bacterial infection⁵⁵. The
683 most common pathogens identified included species in the genera *Mycoplasma*,
684 *Hemophilus*, and *Pseudomonas*. In another study, the most commonly identified co-
685 infections were with *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, and
686 *Haemophilus influenzae*⁵⁷. Using detailed clinical laboratory culture data available for
687 589 subjects hospitalized with respiratory failure due to COVID-19, we showed that
688 higher rates of respiratory infection with other organisms, especially early in their
689 hospitalization, did not occur among subjects with poor clinical outcome. Further, we did
690 not observe an association between positive cultures for any pathogen tested and
691 increased odds of dying in critically ill COVID-19 patients.

692
693 In the subset of COVID-19 patients with BAL samples, we used NGS to identify all
694 potential pathogens and commensals in the lower airways beyond microbial cultures
695 routinely obtained as per clinical care. The RNA virome data showed that SARS-CoV-2
696 dominates the lower airways and was significantly associated with death. A small
697 number of samples had a few sequences that mapped to influenza A or B viruses,
698 suggesting that co-infection with influenza did not occur frequently during this first wave
699 of SARS-CoV-2 infections. Within the DNA virome, there was no significant difference in
700 viruses between the three outcome groups despite the frequent finding of HSV-1.
701 Similarly, when evaluating the metatranscriptome of DNA viruses, there were few
702 differences between the three outcome groups. Although analysis of the phage

703 metagenome data showed no differential enrichment between the three cohorts, we did
704 identify in the metatranscriptome data differentially active phages when comparing the
705 three cohorts, suggesting that changes in the bacterial microbiome may be occurring in
706 critically ill patients with COVID-19. Certain *Staphylococcus* phages were differentially
707 active in those who were ventilated for more than 28 days and in those who died.
708 Interestingly, the bacterial signatures also identified *Mycoplasma salivarium*, a known
709 oral commensal that has previously been associated with ventilator-acquired
710 pneumonia⁶¹, as differentially active in those who died and those who were ventilated
711 for more than 28 days when compared to those ventilated less than 28 days. From
712 previous data published by us, enrichment of the lower airway microbiota with oral
713 commensals was seen to be associated with a pro-inflammatory state in several
714 diseases including lung cancer^{62,63} and non-tuberculosis mycobacterium related
715 bronchiectasis⁶⁴.

716

717 With the use of metagenomic and metatranscriptomic analyses it is also possible to
718 examine how functionally active microbes impact the host⁶⁵. In this cohort of patients,
719 we evaluated the functional profile of the microbiome within the lower airways and its
720 effect on mortality, something that, to our knowledge, had not yet been assessed in
721 COVID-19 patients. The only significant gene function enrichment was found with the
722 metatranscriptome data suggesting that functional activation of microbes can provide
723 further insights into the lower airway microbial environment of patients with worst
724 outcome. Among the pathways that were differentially expressed in those patients with
725 poor outcome, we identified genes associated with degradation, transport, and
726 antimicrobial resistance genes, as well as with signaling. These differences may

727 indicate important functional differences leading to a different metabolic environment in
728 the lower airways that could impact host immune responses. It could also be
729 representative of differences in microbial pressure in patients with higher viral loads and
730 different inflammatory environments.

731
732 In the current investigation, we also characterized the immune response within the
733 lower airways by measuring anti-SARS-CoV-2 Spike antibodies and profiling the host
734 RNA transcriptome. We observed that low levels of anti-Spike and anti-RBD IgG in the
735 lung were associated with poor outcome. Although we did not find a statistically
736 significant association between SARS-CoV-2 neutralizing capacity and poor outcome,
737 levels of SARS-CoV-2 neutralizing antibodies, anti-Spike and anti-RBD antibodies (both
738 IgG and IgA) were negatively correlated with SARS-CoV-2 viability. Prior investigations
739 have suggested that IgA levels are a key driver of neutralization in the mucosa⁶⁶⁻⁶⁸. The
740 differences noted in the current investigation in the IgG pools are intriguing and future
741 work investigating the antibodies generated during SARS-CoV-2 infections will be
742 essential.

743
744 When examining host transcriptomic differences across the different clinical outcome
745 groups, Sirtuin and Ferroptosis signaling pathways were found to be upregulated in the
746 most critically ill COVID-19 patients. Upregulation in the Sirtuin pathway demonstrates
747 an increased host inflammatory response to viral infection²³. In addition, ferroptosis, a
748 recently identified form of non-apoptotic regulated cell death through iron-dependent
749 accumulation of lipid peroxides, has been shown to cause direct lung injury⁶⁹ or
750 pulmonary ischemia-reperfusion injury^{70,71}. Interestingly, there is evidence to support

751 that STAT3⁶⁹ and ACSL4⁷⁰ alleviated ferroptosis-mediated acute lung injury
752 dysregulation, which are both down-regulated in COVID-19 patients with worse clinical
753 outcome. Further analysis showed that there appeared to be an inactivation of
754 phagocytes, neutrophils, granulocytes, and leukocytes, including downregulation of IgG
755 expression levels, with additional mitochondria dysfunction, and down-regulation of
756 Inositol related pathways and noradrenaline/adrenaline degradation. There is evidence
757 that in the neonatal lung, inositol related components exert an anti-inflammatory effect
758 and can prevent acute lung injury^{72,73}.

759
760 Collectively, these data suggest that an imbalance rather than an elevated inflammatory
761 state in the lung is an important marker that predicts poor outcomes in critically ill
762 COVID-19 patients. Indeed, the inferred cell composition analysis from the bulk
763 transcriptome data overall points to a tepid immune response. Memory T cells have
764 been implicated with a robust immune response in SARS-CoV-2.⁷⁴ The deficiency of
765 these memory T cells that we found in the lungs of COVID-19 patients with worse
766 outcome further supports the presence of an ineffective immune response or presence
767 of immune exhaustion. IL4I1, found in the network analysis to be up-regulated in the
768 deceased group in association with SARS-CoV-2, is an immunosuppression enzyme
769 that plays a role in infection and the control of immunopathology⁷⁵. IL4I1 induction has
770 been reported in viral infections with influenza virus⁷⁶. The ISGs and transcriptional
771 regulators *SP110* and *SP140*, both downregulated in the deceased group. play
772 important roles in resisting intracellular pathogens⁷⁷.

773

774 Strikingly, interrogation of the host transcriptomic analysis identified survival-associated
775 differences in interferon-related responses. Our host transcriptomic risk stratified model
776 seems to point to a predictive activation of type I interferon as a prediction for mortality.
777 This might be inconsistent with the current suggestion that, based on systemic levels,
778 early interferon responses are associated with poor outcome in COVID19.^{78,79} Others
779 have suggested that a robust interferon response may lead to a hyperinflammatory
780 state that could be detrimental in the disease process, justifying the use of Janus kinase
781 inhibitor inhibitors in patients with COVID-19.⁸⁰ Studies comparing transcriptomic
782 signatures in BAL of patients with severe COVID-19 and controls have shown activation
783 of type 1 interferons.⁸¹ While further longitudinal data will be needed to clarify the role of
784 interferon signaling on the disease, the data presented here suggest that combining
785 microbial and host signatures could help understand the increase risk for mortality in
786 critically ill COVID-19 patients.

787
788 By collecting BAL samples rather than endotracheal aspirate specimens we were able
789 to ensure extensive sampling of the lower respiratory tract in intubated patients.
790 However,
791 we were limited to samples from intubated patients in whom a clinically indicated
792 bronchoscopy was done to place a percutaneous tracheostomy or for airway clearance.
793 Although this included a large number of patients with various clinical outcomes, those
794 sampled may not be representative of the extremes in the spectrum of disease severity
795 who were most likely not eligible for bronchoscopy. For example, patients that
796 presented with very rapid clinical deterioration and died within the first few days of
797 hospitalization or those who were quickly weaned from mechanical ventilation did not

798 receive bronchoscopy. However, extensive and detailed clinical data were also obtained
799 from intubated COVID-19 patients without bronchoscopy performed within the
800 Manhattan Campus (no bronchoscopy cohort) and from the Long Island cohort for
801 whom bronchoscopies were done without collecting research samples. In both of these
802 cohorts, clinical laboratory culture data did not identify untreated secondary pathogen
803 infections associated with poor outcome.

804
805 The samples used in this investigation were obtained during the first surge of cases of
806 COVID-19 in New York City, and management reflected clinical practices at that time.
807 Among the differences with current therapeutic approaches in COVID-19 patients,
808 corticosteroids and remdesivir, two medications that likely affect the lower airway
809 microbial landscape, were rarely used during the first surge. Other medications, such as
810 antibiotics and anti-inflammatory drugs could affect our findings and we therefore
811 considered them as potential confounders. However, the use of these medications was
812 not found to be associated with clinical outcome. The cross-sectional study design
813 precluded evaluation of the temporal dynamics of the microbial community or the host
814 immune response in this cohort, which could provide important insights into the
815 pathogenesis of this disease. Performing repeated bronchoscopies without a clinical
816 indication would be challenging in these patients and other less invasive methods might
817 need to be considered to study the lower airways at earlier timepoints and serially over
818 time in patients with respiratory failure. It is important to note that there were no
819 statistically significant differences in the timing of sample collection across the three
820 outcome groups.

821

822 In summary, we present here the first evaluation of the lower airway microbiome using a
823 metagenomic and metatranscriptomic approach, along with host immune profiling in
824 critically ill patients with COVID-19 requiring invasive mechanical ventilation. The RNA
825 metatranscriptome analysis showed an association between the abundance of SARS-
826 CoV-2 and mortality, consistent with the signal found when viral load was assessed by
827 targeted rRT-PCR. These viral signatures correlated with lower anti-SARS-CoV-2 Spike
828 IgG and host transcriptomic signatures in the lower airways associated with poor
829 outcome. Importantly, both through culture and NGS data, we did not find evidence for
830 an association between untreated infections with secondary respiratory pathogens and
831 mortality. Together, these data suggest that active lower airway SARS-CoV-2
832 replication and poor SARS-CoV-2-specific antibody responses are the main drivers of
833 increased mortality in COVID-19 patients requiring mechanical ventilation. The potential
834 role of oral commensals such as *Mycoplasma salivarium* need to be explored further. It
835 is possible that *M. salivarium* can impact key immune cells and has recently been
836 reported at a high prevalence in patients with ventilator-acquired pneumonia⁶¹. Critically,
837 our finding that SARS-CoV-2 evades and/or derails effective innate/adaptive immune
838 responses indicates that therapies aiming to control viral replication or induce a targeted
839 antiviral immune response may be the most promising approach for hospitalized
840 patients with SARS-CoV-2 infection requiring invasive mechanical ventilation.

841

842

843 **Methods**

844 **Subjects**

845 Enrolled subjects were 18 years or older, admitted to the intensive care units (ICUs) at
846 NYU Langone Health from March 10th to May 10th, 2020 with a nasal swab confirmed
847 diagnosis of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction
848 (RT-PCR) assay and respiratory failure requiring invasive mechanical ventilation.
849 Samples were obtained during clinically indicated bronchoscopy performed for airway
850 clearance or for percutaneous tracheostomy placement. Surviving subjects signed
851 informed consent to participate in this study. Samples and metadata from subjects who
852 died or were incapacitated were de-identified and included in this study. Comprehensive
853 demographic and clinical data were collected. We also collected longitudinal data on
854 clinical laboratory culture results and treatment. **Supplementary figure 1** shows the
855 distribution of subjects and sampling strategy used for this study. The study protocol
856 was approved by the Institutional Review Board of New York University.

857

858 **Lower airway bronchoscopic sampling procedure**

859 Both background and supraglottic (buccal) samples were obtained prior to the
860 procedure, as previously described⁶². The background samples were obtained by
861 passing sterile saline through the suctioning channel of the bronchoscope prior to the
862 procedure. Bronchoalveolar lavage (BAL) samples were obtained from one lung
863 segment as per discretion of the treating physician as clinically indicated. Samples were
864 then transferred to a BSL3 laboratory for processing. Once there, 2 mL of whole BAL
865 was stored in a tube prefilled with 2 mL of Zymo Research's DNA/RNA Shield™
866 (R1100-250, <https://www.zymoresearch.com/pages/covid-19-efforts>) for RNA/DNA

867 preservation and virus inactivation. In addition, background control samples (saline
868 passed through the bronchoscope prior to bronchoscopy) and supraglottic aspirates
869 were stored in the same RNA/DNA shield. A subset of samples underwent BAL cell
870 separation by centrifugation and cells were cryopreserved in DMSO while acellular BAL
871 fluid was aliquoted for cytokine measurements. A paired blood sample was also
872 obtained in EDTA tubes (Becton Dickinson, ref# 366450) and PAXgene Blood RNA
873 tubes (PreAnalytiX) ref# 762165).

874

875 Viral load detection targeting the N gene

876 SARS-CoV-2 viral load was measured by quantitative real-time reverse transcription
877 polymerase chain reaction (rRT-PCR) targeting the SARS-CoV-2 nucleocapsid (N)
878 gene and an additional primer/probe set to detect the human RNase P gene (RP).
879 Assays were performed using Thermo Fisher Scientific (Waltham, MA) TaqPath 1-Step
880 RT-qPCR Master Mix, CG (catalog number A15299) on the Applied Biosystems (Foster
881 City, CA) 7500 Fast Dx RealTime PCR Instrument. Using the positive controls provided
882 by the CDC, which are normalized to 1000 copies/mL, we converted the different Ct
883 positive to copies/mL. This was done using the DDCT method, applying the formula:
884 $\text{Power} [2, (\text{CT} (\text{sample}, \text{N1 gene}) - \text{CT} (\text{PC}, \text{N1 gene})) - (\text{CT} (\text{sample}, \text{RP gene}) - \text{CT}$
885 $(\text{PC}, \text{RP gene}))] * 1000$.

886

887 SARS-CoV-2 viral viability through measurement of subgenomic transcripts

888 Viral subgenomic mRNA (sgRNA) is transcribed in infected cells and is not packaged
889 into virions. Thus, presence of sgRNA is indicative of active infection of a mammalian

890 cell in samples. We therefore measure sgRNA in all BAL samples obtained targeting the
891 E gene as previously described.²¹ Briefly, five µl RNA was used in a one-step real-time
892 RT-PCR assay to sgRNA (forward primer 5'- CGATCTCTTGTAGATCTGTTCTC-3';
893 reverse primer 5'- ATATTGCAGCAGTACGCACACA-3'; probe 5'-FAM-
894 AACTAGCCATCCTTACTGCGCTTCG-ZEN-IBHQ-3') and using the Quantifast Probe
895 RT-PCR kit (Qiagen) according to instructions of the manufacturer. In each run,
896 standard dilutions of counted RNA standards were run in parallel to calculate copy
897 numbers in the samples.

898

899 DNA/RNA isolation, library preparation and sequencing

900 DNA and RNA were isolated in parallel using zymoBIOMICS™ DNA/RNA Miniprep Kit
901 (Cat: R2002) as per manufacturer's instructions. DNA was then used for whole genome
902 shotgun (WGS) sequencing using it as input into the NexteraXT library preparation kit
903 following the manufacturer's protocol. Libraries were purified using the Agencourt
904 AMPure XP beads (Beckman Coulter, Inc.) to remove fragments below 200 bp. The
905 purified libraries were quantified using the Qubit dsDNA High Sensitivity Assay kit
906 (Invitrogen) and the average fragment length for each library was determined using a
907 High Sensitivity D1000 ScreenTape Assay (Agilent). Samples were added in an
908 equimolar manner to form two sequencing pools. The sequencing pools were quantified
909 using the KAPA Library Quantification Kit for Illumina platforms. The pools were then
910 sequenced on the Illumina Novaseq 6000 in one single run. For RNA sequencing, RNA
911 quantity and integrity were tested with a BioAnalyzer 2100 (Agilent). Among
912 bronchoscope control (BKG) samples, only 5 yielded RNA with sufficient quality and
913 quantity to undergo library preparation and sequencing. The automated Nugen Ovation

914 Trio Low Input RNA method was used for library prep with 3ng total RNA input of each
915 sample. After 6 amplification cycles, samples were sequenced using 2x Novaseq 6000
916 S4 200 cycle Flowcells using PE100 sequencing.

917

918 Microbial community characterization using whole genome shotgun sequencing (WGS)
919 and RNA metatranscriptome

920 For all metagenomic and metatranscriptomic reads, Trimmomatic v0.36⁸², with leading
921 and trailing values set to 3 and minimum length set to 36, was used to remove adaptor
922 sequences. All rRNA reads were then removed from the metatranscriptomic reads using
923 SortMeRNA v4.2.0⁸³ with default settings. Metagenomic and filtered metatranscriptomic
924 reads were mapped to the human genome using Bowtie2 v2.3.4.1⁸⁴ with default settings
925 and all mapping reads were excluded from subsequent microbiome, mycobiome, and
926 virome metagenomic and metatranscriptomic analysis. Technical replicates for each
927 biological sample were pooled together for subsequent analyses. Taxonomic profiles for
928 all metagenomic and metatranscriptomic samples were generated using Kraken
929 v2.0.7⁸⁵ and Bracken v2.5 [<https://doi.org/10.7717/peerj-cs.104>] run with default
930 settings. The database used for quantifying taxonomic profiles was generated using a
931 combined database containing human, bacterial, fungal, archaeal, and viral genomes
932 downloaded from NCBI RefSeq on January 8, 2021. Additionally, genomes for *Candida*
933 *auris* (Genbank: GCA_003013715.2, GCA_008275145.1) and *Pneumocystis jirovecii*
934 (Genbank: GCA_001477535.1) were manually added to the database. Differentially
935 abundant bacterial and viral taxa were identified for the BAL and UA samples groups
936 individually using DESeq2 v1.28.1⁸⁶ with the three group clinical outcome meta-data
937 readouts set as the sample groupings. Significantly differentially abundant taxa

938 contained at a minimum an aggregate of 5 reads across samples and had an FDR
939 $<0.2^{87,88}$.

940
941 For functional microbial profiling, processed sequencing reads were further depleted of
942 human-mapping reads by removing all reads classified as human by Kraken v2.0.7⁸⁵
943 using KrakenTools v0.1-alpha (<https://github.com/jenniferlu717/KrakenTools>). FMAP
944 v0.15⁸⁹ was run on both the metagenomic and metatranscriptomic reads to profile the
945 metabolic pathways present in each sample. FMAP_mapping.pl paired with diamond
946 v0.9.24⁹⁰ and FMAP_quantification.pl were used with default settings to identify and
947 quantify proteins in the Uniref90 database. Using DESeq2 v1.28.1⁸⁶, differentially
948 expressed genes were identified for the BAL samples individually using the three group
949 clinical outcome-metadata readouts for all genes that had an aggregate 5 reads across
950 all samples.

951
952 Antibiotic resistance genes were quantified in all metagenome and metatranscriptome
953 samples using Salmon v1.3.0⁹¹ run with --keepDuplicates for indexing and --libtype A --
954 allowDovetail --meta for quantification. Genes were filtered such that only genes that
955 actively conferred antibiotic resistance were kept. To assess differentially expressed
956 classes of antibiotic resistance genes, gene counts for individual antibiotic resistance
957 genes were collapsed by their conferred antibiotic resistance.

958
959 **Supplementary Figure 1** shows a summary of depth achieved with the parallel WGS
960 and metatranscriptome approach across sample types and the number of reads
961 assigned to different microbial subfractions (bacteria, fungi, DNA viruses, RNA viruses

962 and phages). Further analysis was also done to identify possible contaminants in the
963 metatranscriptome and metagenome datasets. To this end, we compared the relative
964 abundance of taxa between background bronchoscope control and BAL samples. Taxa
965 with median relative abundance greater in background than in BAL were identified as
966 probably contaminant and listed in **Supplementary Table 4**). None of the taxa identified
967 as possible contaminants were removed from the analyzed data but are shown for
968 comparison with signatures identified in the rest of the analyses.

969

970

971 *Anti-Spike SARS-CoV-2 antibody profiling in BAL*

972 BAL samples were heat-treated at 56°C for one hour, and centrifuged at 14000g for 5
973 min. The supernatant was collected and diluted 50-fold in PBST containing 1% skim
974 milk. The diluted samples were incubated at room temperature (R.T.) for 30 min with
975 QBeads DevScreen: SAv (Streptavidin) (Sartorius 90792) that had been loaded with
976 biotinylated Spike, biotinylated RBD or biotin (negative control) in wells of a 96 well HTS
977 filter plate (MSHVN4550). As positive controls, we used CR3022 antibody, that
978 recognizes SARS-CoV-2 Spike and RBD, in human IgG, IgA and IgM formats (Absolute
979 Antibody). After washing the beads, bound antibodies were labeled with anti IgG-
980 DyLight488, anti IgA-PE and anti IgM-PECy7, and the fluorescence intensities were
981 measured in Intellicyt IQue3 (Sartorius). The acquired data [median fluorescence
982 intensity (MFI)] were normalized using the MFI values of the CR3022 antibodies to
983 compensate for variations across plates. **Supplementary Figure 10** shows that the
984 levels of these antibodies were higher in BAL samples of patients with SARS-CoV-2
985 than in BAL samples from 10 uninfected healthy smokers recruited for research

986 bronchoscopy. Details of method development and validation will be described
987 elsewhere (Koide et al. in preparation).

988

989 *SARS-CoV-2 preparation and neutralization assay*

990 icSARS-CoV-2-mNG (isolate USAWA/1/2020, obtained from the UTMB World
991 Reference Center for Emerging Viruses and Arboviruses) was amplified once in Vero E6
992 cells (P1 from the original stock). Briefly, 90-95% confluent T175 flask (Thomas
993 Scientific) of Vero E6 (1×10^7 cells) was inoculated with 50 μ L of icSARS-CoV-2-mNG in
994 5 mL of infection media (DMEM, 2% FBS, 1% NEAA, and 10 mM HEPES) for 1 hour.
995 After 1 hour, 20 mL of infection media was added to the inoculum and cells were
996 incubated 72 hours at 37 °C and 5% CO₂. After 72 hours, the supernatant was collected
997 and the monolayer was frozen and thawed once. Both supernatant and cellular fractions
998 were combined, centrifuged for 5 min at 1200 rpm, and filtered using a 0.22 μ m Steriflip
999 (Millipore). Viral titers were determined by plaque assay in Vero E6 cells. In brief,
1000 220,000 Vero E6 cells/well were seeded in a 24 well plate, 24 hours before inoculation.
1001 Ten-fold dilutions of the virus in DMEM (Corning) were added to the Vero E6
1002 monolayers for 1 hour at 37 °C. Following incubation, cells were overlaid with 0.8%
1003 agarose in DMEM containing 2% FBS (Atlanta biologicals) and incubated at 37 °C for
1004 72 h. The cells were fixed with 10% formalin, the agarose plug removed, and plaques
1005 visualized by crystal violet staining. All procedures including icSARS-CoV-2-mNG virus
1006 were performed using Biosafety Level 3 laboratory conditions.

1007

1008 For SARS-CoV-2 neutralization assays, Vero E6 cells (30,000 cells/well) were seeded
1009 in a 96 well plate 24 h before infection. Two-fold serial dilutions of BAL lysates were

1010 mixed with mixed 1:1 (vol/vol) with SARS-CoV-2 mNG virus (multiplicity of infection,
1011 MOI 0.5), and incubated for 1 h at 37 °C. After incubation, 100 µL of the mixtures of the
1012 antibody and SARS-CoV-2 mNG were added to the Vero E6 monolayers, and cells
1013 were incubated at 37°C. After 20 h, cells were fixed with 4 % formaldehyde (Electron
1014 Microscopy Sciences) at room temperature for 1 h. After fixation, cells were washed
1015 twice with PBS and permeabilized with 0.25% triton-100, stained with DAPI (Thermo),
1016 and quantified on a CellInsight CX7 High-content microscope (Thermo) using a cut-off
1017 for three standard deviations from negative to be scored as an infected cell.

1018

1019 Transcriptome of BAL cells

1020 RNA-Seq was performed on bronchial epithelial cells obtained by airway brushing, as
1021 described⁹²⁻⁹⁴, using the Hi-seq/Illumina platform at the NYU Langone Genomic
1022 Technology Center (data available at Sequence Read Archive: # PRJNA592149).
1023 KEGG^{95,96} annotation was summarized at levels 1 to 3. Genes with an FDR-corrected
1024 adjusted p-value <0.25 were considered significantly differentiated, unless otherwise
1025 specified. Pathway analysis using differentially regulated genes (FDR<0.25) was done
1026 using Ingenuity Pathway Analysis, RRID:SCR_0- at least 1 count per million in at least
1027 two samples were retained. For digital cytometry with CIBERSORTx, a signature matrix
1028 derived from single-cell transcriptome of BAL cells collected from patients with COVID-
1029 19³¹ was first generated with the “Create Signature Matrix” module in the CIBERSORTx
1030 online tool. A maximum of 10 cells per cell type per patient were initially sampled from
1031 the original data and 20 cells per cell type were then used to build the single-cell
1032 reference with the default parameters. Then the “Impute Cell Fractions” module was
1033 used to estimate the absolute cell fraction score of different cell types in bulk

1034 transcriptomes using the single-cell signatures with “S-mode” batch correction and 100
1035 permutations in the absolute mode. Bulk transcriptomes with a significant deconvolution
1036 p-value (≤ 0.05) were retained. For xCell cell type signature enrichment analysis, the
1037 enrichment scores were inferred with built-in signature of cell types detected in the BAL
1038 samples as reported previously³¹. The two-tailed Wilcoxon rank sum test with
1039 Benjamini-Hochberg correction were computed between groups of samples for
1040 comparison.

1041

1042 Microbial and Host predictive modeling

1043 Cox proportional hazards model was used for investigating the association between the
1044 time to death and the relative abundance of each taxon quantified using
1045 metatranscriptomic and metagenomic data separately. We first performed the univariate
1046 screening test to identify significant features associated with the time to death using the
1047 Cox proportion hazards regression model for the relative abundance of taxa from the
1048 RNA and DNA data, and log-transformed count of host transcriptome data, respectively.
1049 Within each type of data, given the p-value cutoff, the features with a p-value less than
1050 the cutoff were selected and integrated as a sub-community. For the RNA and DNA
1051 data, the alpha diversity (Shannon index) was calculated for each sample on the
1052 selected sub-community and the negative of the value was defined as the microbial risk
1053 score, because high alpha diversity indicates low risk of death. For the host
1054 transcriptome data, the log-transformed total count of all selected candidate
1055 transcriptome for each sample was defined as the risk score, since most selected
1056 candidate transcriptomes increased the risk of death. The leave-one-out cross-
1057 validation (LOOCV) was used for the predictions. The p value cutoff was set at the

1058 value which produces the largest AUC (area under the receiver operating characteristic
1059 curve) in predicting the death/survival status using the risk score we constructed over
1060 these features. The additive model was used to integrate when more than one scores
1061 are used for the prediction.

1062

1063 *Multiscale and co-expression network analyses*

1064 Raw counts from the human transcriptome were normalized and converted to log2-
1065 counts per million using limma⁹⁷/voom⁹⁸ (v3.44.1 with R v4.0.0) with standard
1066 parameters. Microbiome abundance information was converted to relative abundance.
1067 Low abundance taxa were removed based on average abundance across all samples to
1068 yield a minimum of 1000 taxa for each metatranscriptome dataset. All datasets were
1069 batch adjusted. Differentially expressed genes (DEGs) and differentially abundant taxa
1070 were called using the DESeq2 package⁸⁶ (v1.28.1), based on the negative binomial (i.e.
1071 Gamma-Poisson) distribution. According to the recommendation by the authors, we
1072 used non-normalized data (i.e. raw gene counts and abundance data), as DESeq2
1073 internally corrects data and performs normalization steps. For this purpose, raw
1074 microbiome abundance data were converted to DESeq2 dds objects using the phyloseq
1075 R library (V1.32.0). Contrasts are based on outcome groups (\leq 28 days MV, $>$ 28 days
1076 MV or death). Differentially expressed genes and differentially abundant tax with FDR of
1077 0.2 or less are considered significant.

1078 Multiscale Embedded Gene Co-Expression Network Analysis (MEGENA)³² was
1079 performed to identify host modules of highly co-expressed genes in SARS-CoV-2
1080 infection. The MEGENA workflow comprises four major steps: 1) Fast Planar Filtered
1081 Network construction (FPFNC), 2) Multiscale Clustering Analysis (MCA), 3) Multiscale

1082 Hub Analysis (MHA), 4) and Cluster-Trait Association Analysis (CTA). The total
1083 relevance of each module to SARS-CoV-2 infection was calculated by using the Product
1084 of Rank method with the combined enrichment of the differentially expressed gene
1085 (DEG) signatures as implemented: $G_j = \prod_i g_{ji}$, where, g_{ji} is the relevance of a
1086 consensus j to a signature i ; and g_{ji} is defined as $(\max_j(r_{ji}) + 1 - r_{ji}) / \sum_j r_{ji}$, where r_{ji}
1087 is the ranking order of the significance level of the overlap between the module j and the
1088 signature.

1089
1090 To functionally annotate gene signatures and gene modules derived from the host
1091 transcriptome data, we performed an enrichment analysis of the established pathways
1092 and signatures—including the gene ontology (GO) categories and MSigDB. The hub
1093 genes in each subnetwork were identified using the adopted Fisher's inverse Chi-
1094 square approach in MEGENA; Bonferroni-corrected p-values smaller than 0.05 were set
1095 as the threshold to identify significant hubs. The correlation between modules, modules
1096 and clinical traits as well as modules and individual taxa were performed using
1097 Spearman correlation. Other correlation measures, such as Pearson correlation or the
1098 Maximal Information Coefficient (MIC)⁹⁹ proved to be inferior for this task. Categorical
1099 trait data was converted to numerical values as suitable.

1100

1101 Data availability

1102 Sequencing data are available in NCBI's Sequence Read Archive under project
1103 numbers PRJNA688510 and PRJNA687506 (RNA and DNA sequencing, respectively).
1104 Codes used for the analyses presented in the current manuscript are available at
1105 https://github.com/segalmicrobiomelab/SARS_CoV2.

1107 **Figure Legends:**

1108

1109 **Figure 1. Associations between culture positivity and clinical outcome.** Odds
1110 ratios and corresponding 95% confidence intervals for rates of culture positivity for the
1111 whole cohort (n=589) during the length of their hospitalization (left) and during the first 2
1112 weeks of hospitalization (right).

1113

1114 **Figure 2. SARS-CoV-2 viral load and virus metatranscriptome analyses.** Copies of
1115 the SARS-CoV-2 N gene per ml, normalized by the Human RNase P gene, comparing
1116 paired upper and lower airway samples **(a)** and levels in BAL comparing clinical
1117 outcome groups **(b)**, *= Mann–Whitney U $p < 0.05$, **= Mann–Whitney U $p < 0.01$). **(c)**
1118 PCoA analysis based on Bray Curtis Dissimilarity index of BAL Metatranscriptome data
1119 comparing clinical outcome (PERMANOVA p-value). Bubble plot showing DESeq
1120 results of RNA viruses **(d)** and expressed DNA phages **(e)** enriched in each clinical
1121 outcome comparisons (bubble size based on median relative abundance for those
1122 found statistically significant).

1123

1124 **Figure 3. Bacteria load and taxonomic compositional analyses.** **(a)** Bacterial load
1125 measured by ddPCR targeting 16S rRNA gene (**= Mann–Whitney U $p < 0.01$). PCoA
1126 analysis based on Bray Curtis Dissimilarity index of BAL Metagenome **(b)** and
1127 Metatranscriptome **(c)** data comparing clinical outcome (PERMANOVA p-value). **(d)**
1128 Gene Set Enrichment Analysis (GSEA) was used to compare the taxonomic signatures
1129 identified in BAL metagenome (diamonds) and metatranscriptome (circles) as distinctly
1130 enriched for comparisons between clinical outcome groups (differential enrichment

1131 performed based on DESeq2 analysis). **(e)** Bubble plot showing DESeq results of
1132 bacteria found concordantly differentially enriched between clinical outcome groups
1133 (bubble size based on median relative abundance for those found statistically
1134 significant).

1135
1136 **Figure 4. Functional microbial compositional analyses.** KOs were summarized to
1137 associated pathways and differential expression was calculated based on DESeq2
1138 analysis. **(a)** Gene Set Enrichment Analysis (GSEA) was used to compare the functional
1139 signatures identified in BAL metagenome and metatranscriptome as distinctly enriched
1140 for comparisons between clinical outcome groups. **(b)** Bubble plot showing DESeq
1141 results of microbial functions found concordantly differentially enriched between clinical
1142 outcome groups (bubble size based on median relative abundance for those found
1143 statistically significant).

1144
1145 **Figure 5. Lower airway host immune profiling in severely ill COVID-19.** **(a)** Levels
1146 of anti-SARS-CoV-2 Spike antibodies in BAL (*= Mann–Whitney U $p < 0.05$). **(b)** Heat-
1147 map of canonical pathway analysis based on Ingenuity Pathway Analysis (IPA,
1148 RRID:SCR_008653) using the lower airway host transcriptome comparing clinical
1149 outcome groups. Orange shows up-regulation of pathway, blue shows down-regulation
1150 of pathway. **(c)** Cell type abundance quantification plots. Comparison of abundance of
1151 mast cells and neutrophils among outcome groups in the BAL fluids of critically ill
1152 patients with COVID-19. Cell type abundance was estimated from the host
1153 transcriptome with CIBERSORTx. Each dot denotes the quantification score of a
1154 sample and boxes depict median and inter-quartile range (*= Mann–Whitney U $p < 0.05$).

1155

1156 **Figure 6. Mortality predictive power of metatranscriptome, metagenome and host**
1157 **transcriptome. (a)** Area under the curved median and confidence interval for receiver
1158 operating characteristic curve analyses calculated from each sequencing datasets as
1159 predictor and mortality as outcome. **(b)** Kaplan-meier survival analyses based on a
1160 cutoff value estimated from features selected from each sequencing dataset. The “High
1161 risk” and “Low risk” groups is the mean of predicted risk scores in all samples. **(c)**
1162 Scatterplot among risk scores from metatranscriptome, metagenome, and host
1163 transcriptome. Dotted line denotes the mean of the risk scores across all subjects,
1164 which is also the threshold for dividing the samples into “High risk” and “Low risk”
1165 groups. **(d)** IPA analyses of host transcriptomic signatures identified as most predictive
1166 of mortality.

1167

1168

1169

1170 **Supplementary Figure Legends:**

1171

1172 **Supplementary Figure 1. Description of patient cohort, samples obtained,**
1173 **analyses performed and sequencing depth.**

1174

1175 **Supplementary Figure 2. SARS-CoV-2 viral load in upper airway samples.** Copies
1176 of the SARS-CoV-2 N gene per ml, normalized by the Human RNase P gene, in upper
1177 airways comparing clinical outcome groups (Mann–Whitney U p-value).

1178

1179 **Supplementary Figure 3. Identification of top taxa found in background samples**
1180 **as compared with BAL and upper airway samples.** Boxplots showing the relative
1181 abundance values in log₁₀ relative abundance of taxa ranked ordered based on
1182 dominance of Background bronchoscope control samples and compared to abundances
1183 in BAL and Upper Airway samples within metatranscriptome **(a)** and metagenome **(b)**
1184 data. Red labels indicate taxa where relative abundance is higher in background
1185 samples than in BAL and therefore considered possible contaminant.

1186

1187 **Supplementary Figure 4. Topographical analyses of Metatranscriptome data.**
1188 Comparison of alpha diversity (Shannon Index, **a**) and beta diversity (Bray Curtis
1189 Dissimilarity index, **b**) across background negative controls (bronchoscope),
1190 bronchoalveolar lavage (BAL) and upper airway (UA) samples (Kruskal-Wallis and
1191 PERMANOVA p-values, respectively). **(c)** Boxplots showing the relative abundance
1192 values in log₁₀ across all metatranscriptome samples for the BAL and Upper Airway
1193 samples. The 50 taxa with the highest relative abundance values in the BAL
1194 metatranscriptome data are displayed; the top 10 in the BAL are highlighted in bold.

1195 Each column consists of four plots displaying in order from top to bottom, the most
1196 abundant RNA vertebrate viruses, DNA phages, bacteria, and fungi identified (from top
1197 to bottom). Numbers in parentheses next to the taxa labels display the ranking in
1198 relative abundance for either the BAL or UA metatranscriptome samples, respectively.

1199

1200 **Supplementary Figure 5. Topographical analyses of Metagenome Data.**

1201 Comparison of alpha diversity (Shannon Index, **a**) and beta diversity (Bray Curtis
1202 Dissimilarity index, **b**) across background negative controls (bronchoscope),
1203 bronchoalveolar lavage (BAL) and upper airway (UA) samples (Kruskal-Wallis and
1204 PERMANOVA p-values, respectively). (c) Boxplots showing the relative abundance
1205 values in log₁₀ across all metagenome samples for the BAL and Upper Airways. The 50
1206 taxa with the highest relative abundance values in the BAL metagenome are displayed;
1207 the top 10 in the BAL are highlighted in bold. Each column consists of two plots
1208 displaying the most abundant bacteria and fungi identified. Numbers in parentheses
1209 next to the taxa labels displays its ranking in relative abundance for either the BAL or
1210 UA metagenome samples, respectively.

1211

1212 **Supplementary Figure 6. Evaluation of associations between the lower airway**

1213 **RNA virome and clinical outcome.** Comparisons between the three clinical outcome
1214 groups was performed for α diversity (Shannon Index, Kruskal-Wallis p-value, left
1215 panel), β diversity (based on Bray Curtis Dissimilarity Index, PERMANOVA p-value,
1216 right panel).

1217

1218 **Supplementary Figure 7. Topographical analyses of the bacterial load.** Bacterial
1219 load measured by ddPCR targeting 16S rRNA gene in background bronchoscope
1220 controls (BKG), lower airway (BAL) and upper airway (UA) samples.

1221
1222 **Supplementary Figure 8. Evaluation of associations between the lower airway
1223 mycobiome and clinical outcome.** Fungal taxonomic data was subtracted from
1224 metagenome and metatranscriptome data from lower airway samples. **(a)** Comparisons
1225 between the three clinical outcome groups was performed for α diversity (Shannon
1226 Index, Kruskal-Wallis p-value, left panel), β diversity (based on Bray Curtis Dissimilarity
1227 Index, PERMANOVA p-value, right panel) on metagenome data. **(b)** Bubble plot
1228 showing DESeq results of fungi enriched in each clinical outcome comparisons based
1229 on metagenome data (bubble size based on median relative abundance for those found
1230 statistically significant). **(c)** Comparisons between the three clinical outcome groups was
1231 performed for α diversity (Shannon Index, Kruskal-Wallis p-value, left panel), β diversity
1232 (based on Bray Curtis Dissimilarity Index, PERMANOVA p-value, right panel) on
1233 metatranscriptome data. **(d)** Bubble plot showing DESeq results of fungi enriched in
1234 each clinical outcome comparisons based on metatranscriptome data (bubble size
1235 based on median relative abundance for those found statistically significant).

1236
1237 **Supplementary Figure 9. Evaluation of associations between the lower airway
1238 antibiotic resistance genes and clinical outcome.** Bubble plot showing DESeq
1239 results of summarized categories of antibiotic resistant microbial genes taken from
1240 MEGARes for the metagenome (top) and metatranscriptome (bottom) data sets for
1241 each clinical outcome comparison (bubble size based on median relative abundance for

1242 those found to be statistically significant). Colored bubbles indicate significantly
1243 enriched antibiotic resistance groups.

1244

1245 **Supplementary Figure 10. Measurement of anti-SARS-CoV-2 Immunoglobulin**
1246 **levels and neutralization activity.** Levels of anti-SARS-CoV-2 Spike **(a)** and anti-
1247 SARS-CoV-2 receptor binding domain (RBD, **b**) antibodies in BAL from non SARS-
1248 CoV-2 infected smoker controls and severely ill COVID-19 intubated patients. Note that
1249 the signals for different isotypes cannot be compared because they are detected with
1250 different reagents. **(c)** Comparisons of levels of anti-SARS-CoV-2 RBD antibodies in
1251 BAL across subjects in different clinical outcome groups (*= Mann–Whitney U $p < 0.05$).
1252 **(d)** Neutralizing activity in BAL samples across subjects in different clinical outcome
1253 groups.

1254

1255 **Supplementary Figure 11. Evaluation for associations between the lower airway**
1256 **host transcriptome and clinical outcome.** **(a)** PCoA (based on Bray Curtis
1257 Dissimilarity Index, PERMANOVA p-value) comparing the three clinical outcome
1258 groups. (b, c, d) Volcano plot comparing lower airway host transcriptome between the
1259 three clinical outcome groups.

1260

1261 **Supplementary Figure 12. Multi-scale cross-kingdom and co-expression**
1262 **networks.** **(a)** The neighborhood 5 cross-kingdom metatranscriptome network centered
1263 around SARS-CoV-2 is shown. Nodes refer to taxa, edges denote co-abundance after
1264 MEGENA. The size of the nodes indicates abundance. Taxa with large nodes are highly
1265 abundant. Node-shapes are according to the legend and refer to different microbial

1266 kingdoms. The differential abundance of taxa in $\log_2(\text{fold change})$ between the
1267 deceased group and the ≤ 28 -day MV groups is shown by node color - red nodes are
1268 taxa abundant in the deceased group compared to the ≤ 28 -day MV group, blue colored
1269 nodes denote the opposite. **(b)** Modules M175 and M718 of the host transcriptome are
1270 shown. The node size refers to the absolute gene expression value. Nodes with wide
1271 node border refer to key regulators/hub genes (see Methods). The differential gene
1272 expression of taxa in $\log_2(\text{fold change})$ between the deceased group and the ≤ 28 -day
1273 MV groups is shown by node color - red nodes are up-regulated in the deceased group
1274 compared to the ≤ 28 -day MV group, blue colored nodes denote the opposite.

1275

1276 **Reference:**

- 1277 1. The, L. Emerging understandings of 2019-nCoV. *Lancet* **395**, 311 (2020).
- 1278 2. WHO coronavirus disease (COVID-19) dashboard. Geneva: World Health Organization, Available
1279 online: <https://covid19.who.int/> (2020).
- 1280 3. Rabaan, A.A., et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. *Infez Med*
1281 **28**, 174-184 (2020).
- 1282 4. Cao, X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* **20**, 269-
1283 270 (2020).
- 1284 5. Arentz, M., et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in
1285 Washington State. *JAMA* **323**, 1612-1614 (2020).
- 1286 6. Bhatraju, P.K., et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J*
1287 *Med* **382**, 2012-2022 (2020).
- 1288 7. Cummings, M.J., et al. Epidemiology, clinical course, and outcomes of critically ill adults with
1289 COVID-19 in New York City: a prospective cohort study. *The Lancet* **395**, 1763-1770 (2020).
- 1290 8. European Society of Anesthesiology. Analysis of COVID-19 data on numbers in intensive care
1291 from Italy: European Society of Anaesthesiology (ESA). Vol. 2020 (2020).
- 1292 9. Grasselli, G., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-
1293 CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* **323**, 1574-1581 (2020).
- 1294 10. Intensive Care National Audit and Research Center UK. ICNARC report on COVID-19 in Critical
1295 Care., Vol. 2020 (2020).
- 1296 11. Richardson, S., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700
1297 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **323**, 2052-2059 (2020).
- 1298 12. Yang, X., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia
1299 in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* **8**,
1300 475-481 (2020).
- 1301 13. Morens, D.M. & Fauci, A.S. The 1918 influenza pandemic: insights for the 21st century. *J Infect*
1302 *Dis* **195**, 1018-1028 (2007).
- 1303 14. Shieh, W.J., et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal
1304 cases in the United States. *Am J Pathol* **177**, 166-175 (2010).
- 1305 15. Dickson, R.P., et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute
1306 respiratory distress syndrome. *Nat Microbiol* **1**, 16113 (2016).
- 1307 16. Kitsios, G.D., et al. Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in
1308 Mechanically Ventilated Patients. *Am J Respir Crit Care Med* **202**, 1666-1677 (2020).
- 1309 17. Dickson, R.P., et al. Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients. *Am J*
1310 *Respir Crit Care Med* **201**, 555-563 (2020).
- 1311 18. Zuo, T., et al. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of
1312 Hospitalization until Discharge. *Gastroenterology* **159**, 1302-1310 e1305 (2020).
- 1313 19. Chen, L., et al. RNA based mNGS approach identifies a novel human coronavirus from two
1314 individual pneumonia cases in 2019 Wuhan outbreak. *Emerg Microbes Infect* **9**, 313-319 (2020).
- 1315 20. Shen, Z., et al. Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in
1316 Patients With Coronavirus Disease 2019. *Clin Infect Dis* **71**, 713-720 (2020).
- 1317 21. Wolfel, R., et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**,
1318 465-469 (2020).
- 1319 22. Yazdi, M., Bouzari, M. & Ghaemi, E.A. Genomic analyses of a novel bacteriophage (VB_PmiS-
1320 Isfahan) within Siphoviridae family infecting *Proteus mirabilis*. *Genomics* **111**, 1283-1291 (2019).
- 1321 23. Budayeva, H.G., Rowland, E.A. & Cristea, I.M. Intricate Roles of Mammalian Sirtuins in Defense
1322 against Viral Pathogens. *J Virol* **90**, 5-8 (2016).

- 1323 24. Dar, H.H., *et al.* Pseudomonas aeruginosa utilizes host polyunsaturated
1324 phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. *J Clin Invest* **128**,
1325 4639-4653 (2018).
- 1326 25. Stoyanovsky, D.A., *et al.* Iron catalysis of lipid peroxidation in ferroptosis: Regulated enzymatic
1327 or random free radical reaction? *Free Radic Biol Med* **133**, 153-161 (2019).
- 1328 26. Burtscher, J., Cappellano, G., Omori, A., Koshiba, T. & Millet, G.P. Mitochondria: In the Cross Fire
1329 of SARS-CoV-2 and Immunity. *iScience* **23**, 101631 (2020).
- 1330 27. Smati, S., *et al.* Relationship between obesity and severe COVID-19 outcomes in patients with
1331 type 2 diabetes: Results from the CORONADO study. *Diabetes Obes Metab* (2020).
- 1332 28. Wargny, M., *et al.* Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the
1333 CORONADO Study. *Diabetes Care* **43**, e174-e177 (2020).
- 1334 29. Newman, A.M., *et al.* Determining cell type abundance and expression from bulk tissues with
1335 digital cytometry. *Nature Biotechnology* **37**, 773-782 (2019).
- 1336 30. Aran, D., Hu, Z. & Butte, A.J. xCell: digitally portraying the tissue cellular heterogeneity
1337 landscape. *Genome Biology* **18**, 220 (2017).
- 1338 31. Liao, M., *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.
1339 *Nature Medicine* **26**, 842-844 (2020).
- 1340 32. Song, W.M. & Zhang, B. Multiscale Embedded Gene Co-expression Network Analysis. *PLoS*
1341 *computational biology* **11**, e1004574 (2015).
- 1342 33. Praest, P., *et al.* The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its
1343 inhibition by viral immune evasion proteins. *Molecular immunology* **101**, 55-64 (2018).
- 1344 34. Sreekumar, P.G., *et al.* The mitochondrial-derived peptide humanin protects RPE cells from
1345 oxidative stress, senescence, and mitochondrial dysfunction. *Investigative ophthalmology &*
1346 *visual science* **57**, 1238-1253 (2016).
- 1347 35. Zhou, J.y., *et al.* Wnt/ β -catenin-mediated heat exposure inhibits intestinal epithelial cell
1348 proliferation and stem cell expansion through endoplasmic reticulum stress. *Journal of cellular*
1349 *physiology* **235**, 5613-5627 (2020).
- 1350 36. Liu, W., *et al.* LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral
1351 innate immunity. *Proceedings of the National Academy of Sciences* **117**, 23695-23706 (2020).
- 1352 37. American Association of Otolaryngology-Head and Neck Surgery. Tracheotomy
1353 Recommendations During the Covid-19 Pandemic. Vol. 2020 (2020).
- 1354 38. Sommer, D.D., *et al.* Recommendations from the CSO-HNS taskforce on performance of
1355 tracheotomy during the COVID-19 pandemic. *J Otolaryngol Head Neck Surg* **49**, 23 (2020).
- 1356 39. Shiba, T., Ghazizadeh, S., Chhetri, D., St John, M. & Long, J. Tracheostomy Considerations during
1357 the COVID-19 Pandemic. *OTO Open* **4**, 2473974X20922528 (2020).
- 1358 40. Ear Nose and Throat Surgery United Kingdom. Tracheostomy guidance during the COVID-19
1359 Pandemic. Vol. 2020 (2020).
- 1360 41. Michetti, C.P., Burlew, C.C., Bulger, E.M., Davis, K.A. & Spain, D.A. Performing tracheostomy
1361 during the Covid-19 pandemic: guidance and recommendations from the Critical Care and Acute
1362 Care Surgery Committees of the American Association for the Surgery of Trauma. *Trauma*
1363 *Surgery & Acute Care Open* **5**, e000482 (2020).
- 1364 42. McGrath, B.A., *et al.* Tracheostomy in the COVID-19 era: global and multidisciplinary guidance.
1365 *Lancet Respir Med*, S2213-2600(2220)30230-30237 (2020).
- 1366 43. Kelleni, M.T. SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality. *J*
1367 *Infect* (2020).
- 1368 44. Fajnzylber, J., *et al.* SARS-CoV-2 viral load is associated with increased disease severity and
1369 mortality. *Nat Commun* **11**, 5493 (2020).
- 1370 45. Bitker, L., *et al.* Protracted viral shedding and viral load are associated with ICU mortality in
1371 Covid-19 patients with acute respiratory failure. *Ann Intensive Care* **10**, 167 (2020).

- 1372 46. Magleby, R., *et al.* Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among
1373 Hospitalized Patients with Coronavirus Disease 2019. *Clin Infect Dis* (2020).
- 1374 47. Westblade, L.F., *et al.* SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without
1375 Cancer Who Are Hospitalized with COVID-19. *Cancer Cell* **38**, 661-671 e662 (2020).
- 1376 48. Pujadas, E., *et al.* SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir Med* **8**, e70
1377 (2020).
- 1378 49. Lee, N., *et al.* Viral loads and duration of viral shedding in adult patients hospitalized with
1379 influenza. *J Infect Dis* **200**, 492-500 (2009).
- 1380 50. Li, C.C., *et al.* Correlation of pandemic (H1N1) 2009 viral load with disease severity and
1381 prolonged viral shedding in children. *Emerging infectious diseases* **16**, 1265-1272 (2010).
- 1382 51. Peiris, J.S., *et al.* Clinical progression and viral load in a community outbreak of coronavirus-
1383 associated SARS pneumonia: a prospective study. *Lancet* **361**, 1767-1772 (2003).
- 1384 52. <https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/>.
- 1385 53. Kim, D., Quinn, J., Pinsky, B., Shah, N.H. & Brown, I. Rates of Co-infection Between SARS-CoV-2
1386 and Other Respiratory Pathogens. *JAMA* **323**, 2085-2086 (2020).
- 1387 54. Kreitmann, L., Monard, C., Dauwalder, O., Simon, M. & Argaud, L. Early bacterial co-infection in
1388 ARDS related to COVID-19. *Intensive Care Med* **46**, 1787-1789 (2020).
- 1389 55. Langford, B.J., *et al.* Bacterial co-infection and secondary infection in patients with COVID-19: a
1390 living rapid review and meta-analysis. *Clin Microbiol Infect* **26**, 1622-1629 (2020).
- 1391 56. Sepulveda, J., *et al.* Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York
1392 City. *J Clin Microbiol* **58**(2020).
- 1393 57. Zhu, X., *et al.* Co-infection with respiratory pathogens among COVID-2019 cases. *Virus Res* **285**,
1394 198005 (2020).
- 1395 58. Zhang, H., *et al.* Risks and features of secondary infections in severe and critical ill COVID-19
1396 patients. *Emerg Microbes Infect* **9**, 1958-1964 (2020).
- 1397 59. Lansbury, L., Lim, B., Baskaran, V. & Lim, W.S. Co-infections in people with COVID-19: a
1398 systematic review and meta-analysis. *J Infect* **81**, 266-275 (2020).
- 1399 60. Koehler, P., *et al.* COVID-19 associated pulmonary aspergillosis. *Mycoses* **63**, 528-534 (2020).
- 1400 61. Nolan, T.J., *et al.* Low-pathogenicity Mycoplasma spp. alter human monocyte and macrophage
1401 function and are highly prevalent among patients with ventilator-acquired pneumonia. *Thorax*
1402 **71**, 594-600 (2016).
- 1403 62. Tsay, J.J., *et al.* Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung
1404 Cancer. *Am J Respir Crit Care Med* **198**, 1188-1198 (2018).
- 1405 63. Tsay, J.J., *et al.* Lower airway dysbiosis affects lung cancer progression. *Cancer Discov* (2020).
- 1406 64. Sulaiman, I., *et al.* Evaluation of the airway microbiome in nontuberculous mycobacteria
1407 disease. *Eur Respir J* **52**(2018).
- 1408 65. Zhang, X., Li, L., Butcher, J., Stintzi, A. & Figeys, D. Advancing functional and translational
1409 microbiome research using meta-omics approaches. *Microbiome* **7**, 154 (2019).
- 1410 66. Sterlin, D., *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Science*
1411 *translational medicine* **13**(2021).
- 1412 67. Wang, Z., *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science translational*
1413 *medicine* **13**(2021).
- 1414 68. Klingler, J., *et al.* Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect Dis*
1415 (2020).
- 1416 69. Qiang, Z., *et al.* Nrf2 and STAT3 Alleviates Ferroptosis-Mediated IIR-ALI by Regulating SLC7A11.
1417 *Oxid Med Cell Longev* **2020**, 5146982 (2020).
- 1418 70. Xu, Y., Li, X., Cheng, Y., Yang, M. & Wang, R. Inhibition of ACSL4 attenuates ferroptotic damage
1419 after pulmonary ischemia-reperfusion. *FASEB J* **34**, 16262-16275 (2020).

- 1420 71. Dong, H., *et al.* Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal
1421 ischemia reperfusion via regulating SLC7A11 and HO-1. *Aging (Albany NY)* **12**, 12943-12959
1422 (2020).
- 1423 72. Hallman, M., Bry, K., Hoppu, K., Lappi, M. & Pohjavuori, M. Inositol supplementation in
1424 premature infants with respiratory distress syndrome. *N Engl J Med* **326**, 1233-1239 (1992).
- 1425 73. Preuss, S., *et al.* Inositol-trisphosphate reduces alveolar apoptosis and pulmonary edema in
1426 neonatal lung injury. *Am J Respir Cell Mol Biol* **47**, 158-169 (2012).
- 1427 74. Sekine, T., *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
1428 COVID-19. *Cell* **183**, 158-168 e114 (2020).
- 1429 75. Molinier-Frenkel, V., Prévost-Blondel, A. & Castellano, F. The IL411 Enzyme: A New Player in the
1430 Immunosuppressive Tumor Microenvironment. *Cells* **8**(2019).
- 1431 76. Baas, T., *et al.* Integrated molecular signature of disease: analysis of influenza virus-infected
1432 macaques through functional genomics and proteomics. *Journal of virology* **80**, 10813-10828
1433 (2006).
- 1434 77. Regad, T. & Chelbi-Alix, M.K. Role and fate of PML nuclear bodies in response to interferon and
1435 viral infections. *Oncogene* **20**, 7274-7286 (2001).
- 1436 78. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
1437 *Science* **370**(2020).
- 1438 79. Zhang, Q., *et al.* Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
1439 *Science* **370**(2020).
- 1440 80. Kalil, A.C., *et al.* Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*
1441 (2020).
- 1442 81. Zhou, Z., *et al.* Heightened Innate Immune Responses in the Respiratory Tract of COVID-19
1443 Patients. *Cell host & microbe* **27**, 883-890 e882 (2020).
- 1444 82. Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence
1445 data. *Bioinformatics* **30**, 2114-2120 (2014).
- 1446 83. Kopylova, E., Noe, L. & Touzet, H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in
1447 metatranscriptomic data. *Bioinformatics* **28**, 3211-3217 (2012).
- 1448 84. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357-
1449 359 (2012).
- 1450 85. Wood, D.E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome*
1451 *biology* **20**, 257 (2019).
- 1452 86. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-
1453 seq data with DESeq2. *Genome biology* **15**, 550 (2014).
- 1454 87. Pavel, A.B., *et al.* Alterations in Bronchial Airway miRNA Expression for Lung Cancer Detection.
1455 *Cancer Prev Res (Phila)* **10**, 651-659 (2017).
- 1456 88. Seumois, G., *et al.* Transcriptional Profiling of Th2 Cells Identifies Pathogenic Features Associated
1457 with Asthma. *J Immunol* **197**, 655-664 (2016).
- 1458 89. Kim, J., Kim, M.S., Koh, A.Y., Xie, Y. & Zhan, X. FMAP: Functional Mapping and Analysis Pipeline
1459 for metagenomics and metatranscriptomics studies. *BMC Bioinformatics* **17**, 420 (2016).
- 1460 90. Buchfink, B., Xie, C. & Huson, D.H. Fast and sensitive protein alignment using DIAMOND. *Nat*
1461 *Methods* **12**, 59-60 (2015).
- 1462 91. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast and bias-
1463 aware quantification of transcript expression. *Nat Methods* **14**, 417-419 (2017).
- 1464 92. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying
1465 mammalian transcriptomes by RNA-Seq. *Nat Methods* **5**, 621-628 (2008).
- 1466 93. Wilhelm, B.T., *et al.* Dynamic repertoire of a eukaryotic transcriptome surveyed at single-
1467 nucleotide resolution. *Nature* **453**, 1239-1243 (2008).

- 1468 94. Sultan, M., *et al.* A global view of gene activity and alternative splicing by deep sequencing of
1469 the human transcriptome. *Science* **321**, 956-960 (2008).
- 1470 95. Tanabe, M. & Kanehisa, M. Using the KEGG database resource. *Curr Protoc Bioinformatics*
1471 **Chapter 1**, Unit1 12 (2012).
- 1472 96. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. & Tanabe, M. KEGG for integration and
1473 interpretation of large-scale molecular data sets. *Nucleic Acids Res* **40**, D109-114 (2012).
- 1474 97. Law, C.W., *et al.* RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. *F1000Res*
1475 **5**(2016).
- 1476 98. Law, C.W., Chen, Y., Shi, W. & Smyth, G.K. voom: Precision weights unlock linear model analysis
1477 tools for RNA-seq read counts. *Genome Biol* **15**, R29 (2014).
- 1478 99. Reshef, D.N., *et al.* Detecting novel associations in large data sets. *Science* **334**, 1518-1524
1479 (2011).

1480

Figure 1

Culture Positivity and risk for poor outcome (n=589)




Figure 1. Associations between culture positivity and clinical outcome. Odds ratios and corresponding 95% confidence intervals for rates of culture positivity for the whole cohort (n=589) during the length of their hospitalization (left) and during the first 2 weeks of hospitalization (right).

Figure 2




Figure 2. SARS-CoV-2 viral load and virus metatranscriptome analyses. Copies of the SARS-CoV-2 N gene per ml, normalized by the Human RNase P gene, comparing paired upper and lower airway samples (a) and levels in BAL comparing clinical outcome groups (b, *= Mann-Whitney U $p<0.05$, **= Mann-Whitney U $p<0.01$). (c) PCoA analysis based on Bray Curtis Dissimilarity index of BAL Metatranscriptome data comparing clinical outcome (PERMANOVA p-value). Bubble plot showing DESeq results of RNA viruses (d) and expressed DNA phages (e) enriched in each clinical outcome comparisons (bubble size based on median relative abundance for those found statistically significant).

Figure 4




Figure 4. Functional microbial compositional analyses. KOs were summarized to associated pathways and differential expression was calculated based on DESeq2 analysis. (a) Gene Set Enrichment Analysis (GSEA) was used to compare the functional signatures identified in BAL metagenome and metatranscriptome as distinctly enriched for comparisons between clinical outcome groups. (b) Bubble plot showing DESeq results of microbial functions found concordantly differentially enriched between clinical outcome groups (bubble size based on median relative abundance for those found statistically significant).

Figure 6




Figure 6. Mortality predictive power of metatranscriptome, metagenome and host transcriptome. (a) Area under the curved median and confidence interval for receiver operating characteristic curve analyses calculated from each sequencing datasets as predictor and mortality as outcome. (b) Kaplan-meier survival analyses based on a cutoff value estimated from features selected from each sequencing dataset. The “High risk” and “Low risk” groups is the mean of predicted risk scores in all samples. (c) Scatterplot among risk scores from metatranscriptome, metagenome, and host transcriptome. Dotted line denotes the mean of the risk scores across all subjects, which is also the threshold for dividing the samples into “High risk” and “Low risk” groups. (d) IPA analyses of host transcriptomic signatures identified as most predictive of mortality.